{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:09:53Z","timestamp":1794640193964,"version":"4.9.1"},"reference-count":382,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"DOI":"10.1007\/s00125-026-06833-z","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:08:41Z","timestamp":1789564121000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The management of type 1 diabetes in adults. The updated 2026 consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8911-6744","authenticated-orcid":false,"given":"Richard I. G.","family":"Holt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9196-9906","authenticated-orcid":false,"given":"J. Hans","family":"DeVries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6066-6360","authenticated-orcid":false,"given":"Amy","family":"Hess-Fischl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1675-8417","authenticated-orcid":false,"given":"Irl B.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5194-9609","authenticated-orcid":false,"given":"M. Sue","family":"Kirkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7199-4079","authenticated-orcid":false,"given":"Tomasz","family":"Klupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0771-5247","authenticated-orcid":false,"given":"Barbara","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1620-8271","authenticated-orcid":false,"given":"Kirsten","family":"N\u00f8rgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5999-0091","authenticated-orcid":false,"given":"Jeremy","family":"Pettus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3407-7263","authenticated-orcid":false,"given":"Eric","family":"Renard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1136-8110","authenticated-orcid":false,"given":"Jay S.","family":"Skyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9563-6762","authenticated-orcid":false,"given":"Frank J.","family":"Snoek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5859-5666","authenticated-orcid":false,"given":"Ruth S.","family":"Weinstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0520-0776","authenticated-orcid":false,"given":"Anne L.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"6833_CR1","doi-asserted-by":"publisher","first-page":"112277","DOI":"10.1016\/j.diabres.2025.112277","volume":"225","author":"GD Ogle","year":"2025","unstructured":"Ogle GD, Wang F, Haynes A et al (2025) Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: results from the International diabetes Federation Atlas, 11th Edition, and the T1D Index Version 3.0. Diabetes Res Clin Pract 225:112277. https:\/\/doi.org\/10.1016\/j.diabres.2025.112277","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"6833_CR2","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.7326\/M23-1707","volume":"176","author":"M Fang","year":"2023","unstructured":"Fang M, Wang D, Echouffo-Tcheugui JB, Selvin E (2023) Age at diagnosis in U.S. adults with type 1 diabetes. Ann Intern Med 176(11):1567\u20131568. https:\/\/doi.org\/10.7326\/M23-1707","journal-title":"Ann Intern Med"},{"issue":"11","key":"6833_CR3","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.2337\/db11-1625","volume":"61","author":"RG Miller","year":"2012","unstructured":"Miller RG, Secrest AM, Sharma RK, Songer TJ, Orchard TJ (2012) Improvements in the life expectancy of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications study cohort. Diabetes 61(11):2987\u20132992. https:\/\/doi.org\/10.2337\/db11-1625","journal-title":"Diabetes"},{"issue":"12","key":"6833_CR4","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1007\/s00125-021-05568-3","volume":"64","author":"RIG Holt","year":"2021","unstructured":"Holt RIG, DeVries JH, Hess-Fischl A et al (2021) The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 64(12):2609\u20132652. https:\/\/doi.org\/10.1007\/s00125-021-05568-3","journal-title":"Diabetologia"},{"issue":"11","key":"6833_CR5","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.2337\/dci21-0043","volume":"44","author":"RIG Holt","year":"2021","unstructured":"Holt RIG, DeVries JH, Hess-Fischl A et al (2021) The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 44(11):2589\u20132625. https:\/\/doi.org\/10.2337\/dci21-0043","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"6833_CR6","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.2337\/dc26-S009","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026) 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2026. Diabetes Care 49(Suppl 1):S183\u2013S215. https:\/\/doi.org\/10.2337\/dc26-S009","journal-title":"Diabetes Care"},{"key":"6833_CR7","unstructured":"International Diabetes Federation (2026) Type 1 diabetes. Available from https:\/\/idf.org\/about-diabetes\/type-1-diabetes\/. Accessed 2 June 2026"},{"key":"6833_CR8","unstructured":"National Institute for Health and Care Excellence (2015) Type 1 diabetes in adults: diagnosis and management. NICE guideline [NG17]. Available from https:\/\/www.nice.org.uk\/guidance\/ng17. Accessed 17 July 2026"},{"issue":"1","key":"6833_CR9","doi-asserted-by":"publisher","first-page":"e1004326","DOI":"10.1371\/journal.pmed.1004326","volume":"21","author":"WT Gattrell","year":"2024","unstructured":"Gattrell WT, Logullo P, van Zuuren EJ et al (2024) ACCORD (ACcurate COnsensus Reporting Document): a reporting guideline for consensus methods in biomedicine developed via a modified Delphi. PLoS Med 21(1):e1004326. https:\/\/doi.org\/10.1371\/journal.pmed.1004326","journal-title":"PLoS Med"},{"issue":"Suppl 1","key":"6833_CR10","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.2337\/dc26-SINT","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026) Introduction and methodology: standards of care in diabetes-2026. Diabetes Care 49(Suppl 1):S1\u2013S5. https:\/\/doi.org\/10.2337\/dc26-SINT","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"6833_CR11","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc26-S002","volume":"49","author":"American Diabetes Association Professional Practice Committee for D","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for D (2026) 2. Diagnosis and classification of diabetes: standards of care in diabetes-2026. Diabetes Care 49(Suppl 1):S27\u2013S49. https:\/\/doi.org\/10.2337\/dc26-S002","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"6833_CR12","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.2337\/dc26-S005","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026) 5. Facilitating positive health behaviors and well-being to improve health outcomes: standards of care in diabetes-2026. Diabetes Care 49(Suppl 1):S89\u2013S131. https:\/\/doi.org\/10.2337\/dc26-S005","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"6833_CR13","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.2337\/dc26-S006","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026) 6. Glycemic goals, hypoglycemia, and hyperglycemic crises: standards of care in diabetes-2026. Diabetes Care 49(Suppl 1):S132\u2013S149. https:\/\/doi.org\/10.2337\/dc26-S006","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"6833_CR14","doi-asserted-by":"publisher","first-page":"S150","DOI":"10.2337\/dc26-S007","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026) 7. Diabetes technology: standards of care in diabetes-2026. Diabetes Care 49(Suppl 1):S150\u2013S165. https:\/\/doi.org\/10.2337\/dc26-S007","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"6833_CR15","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.2337\/dc26-S010","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026) 10. Cardiovascular disease and risk management: standards of care in diabetes-2026. Diabetes Care 49(Suppl 1):S216\u2013S245. https:\/\/doi.org\/10.2337\/dc26-S010","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"6833_CR16","doi-asserted-by":"publisher","first-page":"S246","DOI":"10.2337\/dc26-S011","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026) 11. Chronic kidney disease and risk management: standards of care in diabetes-2026. Diabetes Care 49(Suppl 1):S246\u2013S260. https:\/\/doi.org\/10.2337\/dc26-S011","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"6833_CR17","doi-asserted-by":"publisher","first-page":"S261","DOI":"10.2337\/dc26-S012","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026) 12. Retinopathy, neuropathy, and foot care: standards of care in diabetes-2026. Diabetes Care 49(Suppl 1):S261\u2013S276. https:\/\/doi.org\/10.2337\/dc26-S012","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"6833_CR18","doi-asserted-by":"publisher","first-page":"S277","DOI":"10.2337\/dc26-S013","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026) 13. Older adults: standards of care in diabetes-2026. Diabetes Care 49(Suppl 1):S277\u2013S296. https:\/\/doi.org\/10.2337\/dc26-S013","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"6833_CR19","doi-asserted-by":"publisher","first-page":"S321","DOI":"10.2337\/dc26-S015","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026) 15. Management of diabetes in pregnancy: standards of care in diabetes-2026. Diabetes Care 49(Suppl 1):S321\u2013S338. https:\/\/doi.org\/10.2337\/dc26-S015","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"6833_CR20","doi-asserted-by":"publisher","first-page":"S339","DOI":"10.2337\/dc26-S016","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026) 16. Diabetes care in the hospital: standards of care in diabetes-2026. Diabetes Care 49(Suppl 1):S339\u2013S355. https:\/\/doi.org\/10.2337\/dc26-S016","journal-title":"Diabetes Care"},{"issue":"8","key":"6833_CR21","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.2337\/dci24-0042","volume":"47","author":"M Phillip","year":"2024","unstructured":"Phillip M, Achenbach P, Addala A et al (2024) Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetes Care 47(8):1276\u20131298. https:\/\/doi.org\/10.2337\/dci24-0042","journal-title":"Diabetes Care"},{"issue":"8","key":"6833_CR22","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s00125-024-06183-8","volume":"67","author":"GE Umpierrez","year":"2024","unstructured":"Umpierrez GE, Davis GM, ElSayed NA et al (2024) Hyperglycaemic crises in adults with diabetes: a consensus report. Diabetologia 67(8):1455\u20131479. https:\/\/doi.org\/10.1007\/s00125-024-06183-8","journal-title":"Diabetologia"},{"issue":"12","key":"6833_CR23","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.2337\/dci22-0018","volume":"45","author":"JL Sherr","year":"2022","unstructured":"Sherr JL, Heinemann L, Fleming GA et al (2022) Automated insulin delivery: benefits, challenges, and recommendations. A consensus report of the joint diabetes technology working group of the European Association for the Study of Diabetes and the American Diabetes Association. Diabetes Care 45(12):3058\u20133074. https:\/\/doi.org\/10.2337\/dci22-0018","journal-title":"Diabetes Care"},{"issue":"2","key":"6833_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00125-024-06308-z","volume":"68","author":"O Moser","year":"2025","unstructured":"Moser O, Zaharieva DP, Adolfsson P et al (2025) The use of automated insulin delivery around physical activity and exercise in type 1 diabetes: a position statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD). Diabetologia 68(2):255\u2013280. https:\/\/doi.org\/10.1007\/s00125-024-06308-z","journal-title":"Diabetologia"},{"key":"6833_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00125-019-05034-1","volume":"63","author":"GA Fleming","year":"2020","unstructured":"Fleming GA, Petrie JR, Bergenstal RM, Holl RW, Peters AL, Heinemann L (2020) Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetologia 63:229\u2013241. https:\/\/doi.org\/10.1007\/s00125-019-05034-1","journal-title":"Diabetologia"},{"issue":"3","key":"6833_CR26","doi-asserted-by":"publisher","first-page":"e3743","DOI":"10.1002\/dmrr.3743","volume":"40","author":"A Kovacs","year":"2024","unstructured":"Kovacs A, Bunduc S, Veres DS et al (2024) One third of cases of new-onset diabetic ketosis in adults are associated with ketosis-prone type 2 diabetes-A systematic review and meta-analysis. Diabetes Metab Res Rev 40(3):e3743. https:\/\/doi.org\/10.1002\/dmrr.3743","journal-title":"Diabetes Metab Res Rev"},{"issue":"9","key":"6833_CR27","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1210\/clinem\/dgaf267","volume":"110","author":"AW Michels","year":"2025","unstructured":"Michels AW, Brusko TM, Evans-Molina C, Homann D, Richardson SJ, Powers AC (2025) Challenges and opportunities for understanding the pathogenesis of type 1 diabetes: an Endocrine Society scientific statement. J Clin Endocrinol Metab 110(9):2496\u20132508. https:\/\/doi.org\/10.1210\/clinem\/dgaf267","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"6833_CR28","doi-asserted-by":"publisher","first-page":"476","DOI":"10.2337\/dc14-1952","volume":"38","author":"AK Davis","year":"2015","unstructured":"Davis AK, DuBose SN, Haller MJ et al (2015) Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care 38(3):476\u2013481. https:\/\/doi.org\/10.2337\/dc14-1952","journal-title":"Diabetes Care"},{"issue":"5","key":"6833_CR29","doi-asserted-by":"publisher","first-page":"350","DOI":"10.7326\/0003-4819-144-5-200603070-00011","volume":"144","author":"GE Umpierrez","year":"2006","unstructured":"Umpierrez GE, Smiley D, Kitabchi AE (2006) Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med 144(5):350\u2013357. https:\/\/doi.org\/10.7326\/0003-4819-144-5-200603070-00011","journal-title":"Ann Intern Med"},{"issue":"7","key":"6833_CR30","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00125-019-4863-8","volume":"62","author":"NJ Thomas","year":"2019","unstructured":"Thomas NJ, Lynam AL, Hill AV et al (2019) Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes. Diabetologia 62(7):1167\u20131172. https:\/\/doi.org\/10.1007\/s00125-019-4863-8","journal-title":"Diabetologia"},{"issue":"3","key":"6833_CR31","doi-asserted-by":"publisher","first-page":"276","DOI":"10.2337\/cd18-0088","volume":"37","author":"C Munoz","year":"2019","unstructured":"Munoz C, Floreen A, Garey C et al (2019) Misdiagnosis and diabetic ketoacidosis at diagnosis of type 1 diabetes: patient and caregiver perspectives. Clin Diabetes 37(3):276\u2013281. https:\/\/doi.org\/10.2337\/cd18-0088","journal-title":"Clin Diabetes"},{"issue":"646","key":"6833_CR32","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.3399\/bjgp16X684961","volume":"66","author":"SV Hope","year":"2016","unstructured":"Hope SV, Wienand-Barnett S, Shepherd M et al (2016) Practical Classification Guidelines for Diabetes in patients treated with insulin: a cross-sectional study of the accuracy of diabetes diagnosis. Br J Gen Pract 66(646):e315-322. https:\/\/doi.org\/10.3399\/bjgp16X684961","journal-title":"Br J Gen Pract"},{"issue":"11","key":"6833_CR33","doi-asserted-by":"publisher","first-page":"e009088","DOI":"10.1136\/bmjopen-2015-009088","volume":"5","author":"BM Shields","year":"2015","unstructured":"Shields BM, Peters JL, Cooper C et al (2015) Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. BMJ Open 5(11):e009088. https:\/\/doi.org\/10.1136\/bmjopen-2015-009088","journal-title":"BMJ Open"},{"issue":"2","key":"6833_CR34","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S2213-8587(17)30362-5","volume":"6","author":"NJ Thomas","year":"2018","unstructured":"Thomas NJ, Jones SE, Weedon MN, Shields BM, Oram RA, Hattersley AT (2018) Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. Lancet Diabetes Endocrinol 6(2):122\u2013129. https:\/\/doi.org\/10.1016\/S2213-8587(17)30362-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"6833_CR35","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.2337\/diacare.24.9.1522","volume":"24","author":"TA Hillier","year":"2001","unstructured":"Hillier TA, Pedula KL (2001) Characteristics of an adult population with newly diagnosed type 2 diabetes: the relation of obesity and age of onset. Diabetes Care 24(9):1522\u20131527. https:\/\/doi.org\/10.2337\/diacare.24.9.1522","journal-title":"Diabetes Care"},{"issue":"1","key":"6833_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/s0002-9343(96)00076-9","volume":"101","author":"SA Westphal","year":"1996","unstructured":"Westphal SA (1996) The occurrence of diabetic ketoacidosis in non-insulin-dependent diabetes and newly diagnosed diabetic adults. Am J Med 101(1):19\u201324. https:\/\/doi.org\/10.1016\/s0002-9343(96)00076-9","journal-title":"Am J Med"},{"issue":"8","key":"6833_CR37","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00125-003-1158-9","volume":"46","author":"T Nakagami","year":"2003","unstructured":"Nakagami T, Qiao Q, Carstensen B et al (2003) Age, body mass index and Type 2 diabetes-associations modified by ethnicity. Diabetologia 46(8):1063\u20131070. https:\/\/doi.org\/10.1007\/s00125-003-1158-9","journal-title":"Diabetologia"},{"issue":"1","key":"6833_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/1047-2797(93)90004-n","volume":"3","author":"MJ Prior","year":"1993","unstructured":"Prior MJ, Prout T, Miller D, Ewart R, Kumar D (1993) C-peptide and the classification of diabetes mellitus patients in the Early Treatment Diabetic Retinopathy Study. Report number 6. The ETDRS Research Group. Ann Epidemiol 3(1):9\u201317. https:\/\/doi.org\/10.1016\/1047-2797(93)90004-n","journal-title":"Ann Epidemiol"},{"issue":"9","key":"6833_CR39","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s00125-020-05181-w","volume":"63","author":"WK Chung","year":"2020","unstructured":"Chung WK, Erion K, Florez JC et al (2020) Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 63(9):1671\u20131693. https:\/\/doi.org\/10.1007\/s00125-020-05181-w","journal-title":"Diabetologia"},{"issue":"10","key":"6833_CR40","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.2337\/dbi20-0017","volume":"69","author":"R Buzzetti","year":"2020","unstructured":"Buzzetti R, Tuomi T, Mauricio D et al (2020) Management of latent autoimmune diabetes in adults: a consensus statement from an international expert panel. Diabetes 69(10):2037\u20132047. https:\/\/doi.org\/10.2337\/dbi20-0017","journal-title":"Diabetes"},{"issue":"6","key":"6833_CR41","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.2337\/dc20-2834","volume":"44","author":"AG Jones","year":"2021","unstructured":"Jones AG, McDonald TJ, Shields BM, Hagopian W, Hattersley AT (2021) Latent Autoimmune Diabetes of Adults (LADA) is likely to represent a mixed population of autoimmune (Type 1) and nonautoimmune (Type 2) diabetes. Diabetes Care 44(6):1243\u20131251. https:\/\/doi.org\/10.2337\/dc20-2834","journal-title":"Diabetes Care"},{"issue":"9","key":"6833_CR42","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.2337\/diacare.23.9.1326","volume":"23","author":"E Sabbah","year":"2000","unstructured":"Sabbah E, Savola K, Ebeling T et al (2000) Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes. Diabetes Care 23(9):1326\u20131332. https:\/\/doi.org\/10.2337\/diacare.23.9.1326","journal-title":"Diabetes Care"},{"issue":"1","key":"6833_CR43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1210\/jc.2009-1365","volume":"95","author":"PJ Bingley","year":"2010","unstructured":"Bingley PJ (2010) Clinical applications of diabetes antibody testing. J Clin Endocrinol Metab 95(1):25\u201333. https:\/\/doi.org\/10.1210\/jc.2009-1365","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"6833_CR44","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2337\/diacare.22.3.409","volume":"22","author":"B Littorin","year":"1999","unstructured":"Littorin B, Sundkvist G, Hagopian W et al (1999) Islet cell and glutamic acid decarboxylase antibodies present at diagnosis of diabetes predict the need for insulin treatment. A cohort study in young adults whose disease was initially labeled as type 2 or unclassifiable diabetes. Diabetes Care 22(3):409\u2013412. https:\/\/doi.org\/10.2337\/diacare.22.3.409","journal-title":"Diabetes Care"},{"issue":"9","key":"6833_CR45","doi-asserted-by":"publisher","first-page":"e031586","DOI":"10.1136\/bmjopen-2019-031586","volume":"9","author":"A Lynam","year":"2019","unstructured":"Lynam A, McDonald T, Hill A et al (2019) Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18\u201350 years. BMJ Open 9(9):e031586. https:\/\/doi.org\/10.1136\/bmjopen-2019-031586","journal-title":"BMJ Open"},{"issue":"4","key":"6833_CR46","doi-asserted-by":"publisher","first-page":"988","DOI":"10.2337\/dc10-1903","volume":"34","author":"DM Tridgell","year":"2011","unstructured":"Tridgell DM, Spiekerman C, Wang RS, Greenbaum CJ (2011) Interaction of onset and duration of diabetes on the percent of GAD and IA-2 antibody-positive subjects in the type 1 diabetes genetics consortium database. Diabetes Care 34(4):988\u2013993. https:\/\/doi.org\/10.2337\/dc10-1903","journal-title":"Diabetes Care"},{"issue":"2","key":"6833_CR47","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s00125-022-05823-1","volume":"66","author":"NJ Thomas","year":"2023","unstructured":"Thomas NJ, Walkey HC, Kaur A et al (2023) The relationship between islet autoantibody status and the genetic risk of type 1 diabetes in adult-onset type 1 diabetes. Diabetologia 66(2):310\u2013320. https:\/\/doi.org\/10.1007\/s00125-022-05823-1","journal-title":"Diabetologia"},{"issue":"12","key":"6833_CR48","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1007\/s00125-023-06004-4","volume":"66","author":"NJ Thomas","year":"2023","unstructured":"Thomas NJ, Jones AG (2023) The challenges of identifying and studying type 1 diabetes in adults. Diabetologia 66(12):2200\u20132212. https:\/\/doi.org\/10.1007\/s00125-023-06004-4","journal-title":"Diabetologia"},{"issue":"12","key":"6833_CR49","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.2337\/dc22-0623","volume":"45","author":"RJ Eason","year":"2022","unstructured":"Eason RJ, Thomas NJ, Hill AV et al (2022) Routine islet autoantibody testing in clinically diagnosed adult-onset type 1 diabetes can help identify misclassification and the possibility of successful insulin cessation. Diabetes Care 45(12):2844\u20132851. https:\/\/doi.org\/10.2337\/dc22-0623","journal-title":"Diabetes Care"},{"issue":"6","key":"6833_CR50","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1515\/cclm-2024-1260","volume":"63","author":"C Rohlfing","year":"2025","unstructured":"Rohlfing C, Petroski G, Connolly SM, Hanson S, Little RR, Kabytaev K (2025) A comparative analysis of current capital ES, Cyrillic-peptide assays compared to a reference method: can we overcome inertia to standardization? Clin Chem Lab Med 63(6):1124\u20131131. https:\/\/doi.org\/10.1515\/cclm-2024-1260","journal-title":"Clin Chem Lab Med"},{"key":"6833_CR51","doi-asserted-by":"publisher","unstructured":"Schleicher E, Kabytaev K, Nauck M et al (2025) Call for standardization of C-peptide measurement. J Diabetes Sci Technol 19322968251362848. https:\/\/doi.org\/10.1177\/19322968251362848","DOI":"10.1177\/19322968251362848"},{"issue":"9","key":"6833_CR52","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1373\/clinchem.2016.269274","volume":"63","author":"RR Little","year":"2017","unstructured":"Little RR, Wielgosz RI, Josephs R et al (2017) Implementing a reference measurement system for c-peptide: successes and lessons learned. Clin Chem 63(9):1447\u20131456. https:\/\/doi.org\/10.1373\/clinchem.2016.269274","journal-title":"Clin Chem"},{"issue":"7","key":"6833_CR53","doi-asserted-by":"publisher","first-page":"e14449","DOI":"10.1111\/dme.14449","volume":"38","author":"E Foteinopoulou","year":"2021","unstructured":"Foteinopoulou E, Clarke CAL, Pattenden RJ et al (2021) Impact of routine clinic measurement of serum C-peptide in people with a clinician-diagnosis of type 1 diabetes. Diabet Med 38(7):e14449. https:\/\/doi.org\/10.1111\/dme.14449","journal-title":"Diabet Med"},{"issue":"12","key":"6833_CR54","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.2337\/dc06-0749","volume":"29","author":"A Balasubramanyam","year":"2006","unstructured":"Balasubramanyam A, Garza G, Rodriguez L et al (2006) Accuracy and predictive value of classification schemes for ketosis-prone diabetes. Diabetes Care 29(12):2575\u20132579. https:\/\/doi.org\/10.2337\/dc06-0749","journal-title":"Diabetes Care"},{"issue":"5","key":"6833_CR55","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1463-1326.2008.00975.x","volume":"11","author":"C Hohberg","year":"2009","unstructured":"Hohberg C, Pfutzner A, Forst T et al (2009) Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual beta-cell function: results from the PioSwitch study. Diabetes Obes Metab 11(5):464\u2013471. https:\/\/doi.org\/10.1111\/j.1463-1326.2008.00975.x","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"6833_CR56","doi-asserted-by":"publisher","first-page":"305","DOI":"10.4158\/EP.5.6.305","volume":"5","author":"A Lee","year":"1999","unstructured":"Lee A, Morley J (1999) Classification of type 2 diabetes by clinical response to metformin-troglitazone combination and C-Peptide criteria. Endocr Pract 5(6):305\u2013313. https:\/\/doi.org\/10.4158\/EP.5.6.305","journal-title":"Endocr Pract"},{"issue":"2","key":"6833_CR57","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4158\/EP.4.2.82","volume":"4","author":"DS Bell","year":"1998","unstructured":"Bell DS, Mayo MS (1998) Improved glycemic control with use of oral hypoglycemic therapy with or without insulin. Endocr Pract 4(2):82\u201385. https:\/\/doi.org\/10.4158\/EP.4.2.82","journal-title":"Endocr Pract"},{"issue":"9","key":"6833_CR58","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.2337\/dc25-0214","volume":"48","author":"AEJ Hendriks","year":"2025","unstructured":"Hendriks AEJ, Marcovecchio ML, Evans ML et al (2025) Early detection of beta-cell decline using home dried-blood-spot C-peptide levels in new-onset type 1 diabetes. Diabetes Care 48(9):1484\u20131492. https:\/\/doi.org\/10.2337\/dc25-0214","journal-title":"Diabetes Care"},{"issue":"8","key":"6833_CR59","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2337\/dc17-0224","volume":"40","author":"BM Shields","year":"2017","unstructured":"Shields BM, Shepherd M, Hudson M et al (2017) Population-based assessment of a biomarker-based screening pathway to aid diagnosis of monogenic diabetes in young-onset patients. Diabetes Care 40(8):1017\u20131025. https:\/\/doi.org\/10.2337\/dc17-0224","journal-title":"Diabetes Care"},{"issue":"9392","key":"6833_CR60","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S0140-6736(03)14571-0","volume":"362","author":"ER Pearson","year":"2003","unstructured":"Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT (2003) Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 362(9392):1275\u20131281. https:\/\/doi.org\/10.1016\/S0140-6736(03)14571-0","journal-title":"Lancet"},{"issue":"8","key":"6833_CR61","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/pedi.13426","volume":"23","author":"SAW Greeley","year":"2022","unstructured":"Greeley SAW, Polak M, Njolstad PR et al (2022) ISPAD Clinical Practice Consensus Guidelines 2022: the diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 23(8):1188\u20131211. https:\/\/doi.org\/10.1111\/pedi.13426","journal-title":"Pediatr Diabetes"},{"issue":"9997","key":"6833_CR62","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)60098-8","volume":"386","author":"E De Franco","year":"2015","unstructured":"De Franco E, Flanagan SE, Houghton JA et al (2015) The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study. Lancet 386(9997):957\u2013963. https:\/\/doi.org\/10.1016\/S0140-6736(15)60098-8","journal-title":"Lancet"},{"issue":"5","key":"6833_CR63","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1056\/NEJMoa061759","volume":"355","author":"ER Pearson","year":"2006","unstructured":"Pearson ER, Flechtner I, Njolstad PR et al (2006) Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355(5):467\u2013477. https:\/\/doi.org\/10.1056\/NEJMoa061759","journal-title":"N Engl J Med"},{"issue":"1","key":"6833_CR64","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2337\/dc19-0747","volume":"43","author":"A Carlsson","year":"2020","unstructured":"Carlsson A, Shepherd M, Ellard S et al (2020) Absence of islet autoantibodies and modestly raised glucose values at diabetes diagnosis should lead to testing for MODY: lessons from a 5-year pediatric Swedish national cohort study. Diabetes Care 43(1):82\u201389. https:\/\/doi.org\/10.2337\/dc19-0747","journal-title":"Diabetes Care"},{"issue":"5","key":"6833_CR65","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00125-011-2418-8","volume":"55","author":"BM Shields","year":"2012","unstructured":"Shields BM, McDonald TJ, Ellard S, Campbell MJ, Hyde C, Hattersley AT (2012) The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes. Diabetologia 55(5):1265\u20131272. https:\/\/doi.org\/10.1007\/s00125-011-2418-8","journal-title":"Diabetologia"},{"issue":"10","key":"6833_CR66","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1007\/s00125-016-4056-7","volume":"59","author":"S Misra","year":"2016","unstructured":"Misra S, Shields B, Colclough K et al (2016) South Asian individuals with diabetes who are referred for MODY testing in the UK have a lower mutation pick-up rate than white European people. Diabetologia 59(10):2262\u20132265. https:\/\/doi.org\/10.1007\/s00125-016-4056-7","journal-title":"Diabetologia"},{"issue":"2","key":"6833_CR67","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2337\/dc10-1293","volume":"34","author":"RE Besser","year":"2011","unstructured":"Besser RE, Shepherd MH, McDonald TJ et al (2011) Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-alpha\/hepatocyte nuclear factor 4-alpha maturity-onset diabetes of the young from long-duration type 1 diabetes. Diabetes Care 34(2):286\u2013291. https:\/\/doi.org\/10.2337\/dc10-1293","journal-title":"Diabetes Care"},{"issue":"9","key":"6833_CR68","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/j.1464-5491.2011.03287.x","volume":"28","author":"TJ McDonald","year":"2011","unstructured":"McDonald TJ, Colclough K, Brown R et al (2011) Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes. Diabet Med 28(9):1028\u20131033. https:\/\/doi.org\/10.1111\/j.1464-5491.2011.03287.x","journal-title":"Diabet Med"},{"issue":"6","key":"6833_CR69","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.2337\/dc11-1243","volume":"35","author":"G Thanabalasingham","year":"2012","unstructured":"Thanabalasingham G, Pal A, Selwood MP et al (2012) Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young. Diabetes Care 35(6):1206\u20131212. https:\/\/doi.org\/10.2337\/dc11-1243","journal-title":"Diabetes Care"},{"issue":"10","key":"6833_CR70","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.2337\/dc15-1419","volume":"38","author":"RA Insel","year":"2015","unstructured":"Insel RA, Dunne JL, Atkinson MA et al (2015) Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 38(10):1964\u20131974. https:\/\/doi.org\/10.2337\/dc15-1419","journal-title":"Diabetes Care"},{"issue":"9","key":"6833_CR71","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1136\/archdischild-2021-321864","volume":"107","author":"REJ Besser","year":"2022","unstructured":"Besser REJ, Ng SM, Gregory JW, Dayan CM, Randell T, Barrett T (2022) General population screening for childhood type 1 diabetes: is it time for a UK strategy? Arch Dis Child 107(9):790\u2013795. https:\/\/doi.org\/10.1136\/archdischild-2021-321864","journal-title":"Arch Dis Child"},{"issue":"8","key":"6833_CR72","doi-asserted-by":"publisher","first-page":"6836","DOI":"10.1111\/dom.70688","volume":"28","author":"C Mathieu","year":"2026","unstructured":"Mathieu C, Cherubini V, Kapellen T et al (2026) Advancing early-stage type 1 diabetes care: future focused pathways for identification, screening, diagnosis, and monitoring. Diabetes Obes Metab 28(8):6836\u20136849. https:\/\/doi.org\/10.1111\/dom.70688","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"6833_CR73","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1159\/000543035","volume":"97","author":"MJ Haller","year":"2024","unstructured":"Haller MJ, Bell KJ, Besser REJ et al (2024) ISPAD clinical practice consensus guidelines 2024: screening, staging, and strategies to preserve beta-cell function in children and adolescents with type 1 diabetes. Horm Res Paediatr 97(6):529\u2013545. https:\/\/doi.org\/10.1159\/000543035","journal-title":"Horm Res Paediatr"},{"issue":"10","key":"6833_CR74","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s001250051044","volume":"41","author":"The Eurodiab Ace Study Group and The Eurodiab Ace Substudy 2 Study Group","year":"1998","unstructured":"The Eurodiab Ace Study Group and The Eurodiab Ace Substudy 2 Study Group (1998) Familial risk of type I diabetes in European children. Diabetologia 41(10):1151\u20131156. https:\/\/doi.org\/10.1007\/s001250051044","journal-title":"Diabetologia"},{"issue":"5","key":"6833_CR75","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.2337\/dc20-1829","volume":"44","author":"B Karges","year":"2021","unstructured":"Karges B, Prinz N, Placzek K et al (2021) A comparison of familial and sporadic type 1 diabetes among young patients. Diabetes Care 44(5):1116\u20131124. https:\/\/doi.org\/10.2337\/dc20-1829","journal-title":"Diabetes Care"},{"issue":"9","key":"6833_CR76","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1007\/s00125-009-1427-3","volume":"52","author":"K Hemminki","year":"2009","unstructured":"Hemminki K, Li X, Sundquist J, Sundquist K (2009) Familial association between type 1 diabetes and other autoimmune and related diseases. Diabetologia 52(9):1820\u20131828. https:\/\/doi.org\/10.1007\/s00125-009-1427-3","journal-title":"Diabetologia"},{"issue":"11","key":"6833_CR77","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1007\/s00125-019-4952-8","volume":"62","author":"M Turtinen","year":"2019","unstructured":"Turtinen M, Harkonen T, Parkkola A, Ilonen J, Knip M, Finnish Pediatric Diabetes R (2019) Characteristics of familial type 1 diabetes: effects of the relationship to the affected family member on phenotype and genotype at diagnosis. Diabetologia 62(11):2025\u20132039. https:\/\/doi.org\/10.1007\/s00125-019-4952-8","journal-title":"Diabetologia"},{"issue":"5","key":"6833_CR78","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00228-023-03474-8","volume":"79","author":"S Misra","year":"2023","unstructured":"Misra S, Shukla AK (2023) Teplizumab: type 1 diabetes mellitus preventable? Eur J Clin Pharmacol 79(5):609\u2013616. https:\/\/doi.org\/10.1007\/s00228-023-03474-8","journal-title":"Eur J Clin Pharmacol"},{"issue":"14","key":"6833_CR79","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"Diabetes Control and Complications Trial Research Group","year":"1993","unstructured":"Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329(14):977\u2013986. https:\/\/doi.org\/10.1056\/NEJM199309303291401","journal-title":"N Engl J Med"},{"issue":"5","key":"6833_CR80","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2337\/dc15-1990","volume":"39","author":"Diabetes Control Complications Trial Epidemiology of Diabetes Interventions Complications Study Research Group","year":"2016","unstructured":"Diabetes Control Complications Trial Epidemiology of Diabetes Interventions Complications Study Research Group (2016) Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT\/EDIC study 30-year follow-up. Diabetes Care 39(5):686\u2013693. https:\/\/doi.org\/10.2337\/dc15-1990","journal-title":"Diabetes Care"},{"issue":"2","key":"6833_CR81","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2337\/dc21-0507","volume":"45","author":"FS Malik","year":"2022","unstructured":"Malik FS, Sauder KA, Isom S et al (2022) Trends in glycemic control among youth and young adults with diabetes: the SEARCH for diabetes in youth study. Diabetes Care 45(2):285\u2013294. https:\/\/doi.org\/10.2337\/dc21-0507","journal-title":"Diabetes Care"},{"issue":"2","key":"6833_CR82","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1089\/dia.2018.0384","volume":"21","author":"NC Foster","year":"2019","unstructured":"Foster NC, Beck RW, Miller KM et al (2019) State of type 1 diabetes management and outcomes from the T1D exchange in 2016\u20132018. Diabetes Technol Ther 21(2):66\u201372. https:\/\/doi.org\/10.1089\/dia.2018.0384","journal-title":"Diabetes Technol Ther"},{"issue":"3","key":"6833_CR83","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1177\/19322968221076874","volume":"17","author":"FW Udsen","year":"2023","unstructured":"Udsen FW, Hangaard S, Bender C et al (2023) The effectiveness of telemedicine solutions in type 1 diabetes management: a systematic review and meta-analysis. J Diabetes Sci Technol 17(3):782\u2013793. https:\/\/doi.org\/10.1177\/19322968221076874","journal-title":"J Diabetes Sci Technol"},{"issue":"1","key":"6833_CR84","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S2213-8587(21)00312-0","volume":"10","author":"KK Hood","year":"2022","unstructured":"Hood KK, Wong JJ (2022) Telehealth for people with diabetes: poised for a new approach. Lancet Diabetes Endocrinol 10(1):8\u201310. https:\/\/doi.org\/10.1016\/S2213-8587(21)00312-0","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"6833_CR85","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S2213-8587(17)30260-7","volume":"6","author":"DC Duke","year":"2018","unstructured":"Duke DC, Barry S, Wagner DV, Speight J, Choudhary P, Harris MA (2018) Distal technologies and type 1 diabetes management. Lancet Diabetes Endocrinol 6(2):143\u2013156. https:\/\/doi.org\/10.1016\/S2213-8587(17)30260-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"6833_CR86","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1177\/193229681000400323","volume":"4","author":"F Verhoeven","year":"2010","unstructured":"Verhoeven F, Tanja-Dijkstra K, Nijland N, Eysenbach G, van Gemert-Pijnen L (2010) Asynchronous and synchronous teleconsultation for diabetes care: a systematic literature review. J Diabetes Sci Technol 4(3):666\u2013684. https:\/\/doi.org\/10.1177\/193229681000400323","journal-title":"J Diabetes Sci Technol"},{"issue":"2","key":"6833_CR87","doi-asserted-by":"publisher","first-page":"484","DOI":"10.2337\/dc21-2396","volume":"45","author":"J Davis","year":"2022","unstructured":"Davis J, Fischl AH, Beck J et al (2022) 2022 National standards for diabetes self-management education and support. Diabetes Care 45(2):484\u2013494. https:\/\/doi.org\/10.2337\/dc21-2396","journal-title":"Diabetes Care"},{"issue":"2","key":"6833_CR88","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S2213-8587(17)30239-5","volume":"6","author":"S Chatterjee","year":"2018","unstructured":"Chatterjee S, Davies MJ, Heller S, Speight J, Snoek FJ, Khunti K (2018) Diabetes structured self-management education programmes: a narrative review and current innovations. Lancet Diabetes Endocrinol 6(2):130\u2013142. https:\/\/doi.org\/10.1016\/S2213-8587(17)30239-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"6833_CR89","doi-asserted-by":"publisher","first-page":"270","DOI":"10.2337\/dc12-0080","volume":"36","author":"D Cooke","year":"2013","unstructured":"Cooke D, Bond R, Lawton J et al (2013) Structured type 1 diabetes education delivered within routine care: impact on glycemic control and diabetes-specific quality of life. Diabetes Care 36(2):270\u2013272. https:\/\/doi.org\/10.2337\/dc12-0080","journal-title":"Diabetes Care"},{"issue":"99","key":"6833_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19990","volume":"19","author":"S Michie","year":"2015","unstructured":"Michie S, Wood CE, Johnston M, Abraham C, Francis JJ, Hardeman W (2015) Behaviour change techniques: the development and evaluation of a taxonomic method for reporting and describing behaviour change interventions (a suite of five studies involving consensus methods, randomised controlled trials and analysis of qualitative data). Health Technol Assess 19(99):1\u2013188. https:\/\/doi.org\/10.3310\/hta19990","journal-title":"Health Technol Assess"},{"issue":"6","key":"6833_CR91","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1177\/1932296819834054","volume":"13","author":"M Joubert","year":"2019","unstructured":"Joubert M, Benhamou PY, Schaepelynck P et al (2019) Remote monitoring of diabetes: a cloud-connected digital system for individuals with diabetes and their health care providers. J Diabetes Sci Technol 13(6):1161\u20131168. https:\/\/doi.org\/10.1177\/1932296819834054","journal-title":"J Diabetes Sci Technol"},{"issue":"1","key":"6833_CR92","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1177\/19322968221093078","volume":"18","author":"V Sharma","year":"2024","unstructured":"Sharma V, Feldman M, Sharma R (2024) Telehealth technologies in diabetes self-management and education. J Diabetes Sci Technol 18(1):148\u2013158. https:\/\/doi.org\/10.1177\/19322968221093078","journal-title":"J Diabetes Sci Technol"},{"issue":"7","key":"6833_CR93","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.2337\/dci20-0023","volume":"43","author":"MA Powers","year":"2020","unstructured":"Powers MA, Bardsley JK, Cypress M et al (2020) Diabetes self-management education and support in adults with type 2 diabetes: a consensus report of the American Diabetes Association, the Association of Diabetes Care & Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association. Diabetes Care 43(7):1636\u20131649. https:\/\/doi.org\/10.2337\/dci20-0023","journal-title":"Diabetes Care"},{"issue":"3","key":"6833_CR94","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2337\/ds18-0101","volume":"32","author":"DT Ahn","year":"2019","unstructured":"Ahn DT, Stahl R (2019) Is there an app for that? The pros and cons of diabetes smartphone apps and how to integrate them into clinical practice. Diabetes Spectr 32(3):231\u2013236. https:\/\/doi.org\/10.2337\/ds18-0101","journal-title":"Diabetes Spectr"},{"issue":"12","key":"6833_CR95","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s00592-017-1051-5","volume":"54","author":"E Mozzillo","year":"2017","unstructured":"Mozzillo E, Zito E, Maffeis C et al (2017) Unhealthy lifestyle habits and diabetes-specific health-related quality of life in youths with type 1 diabetes. Acta Diabetol 54(12):1073\u20131080. https:\/\/doi.org\/10.1007\/s00592-017-1051-5","journal-title":"Acta Diabetol"},{"key":"6833_CR96","doi-asserted-by":"publisher","first-page":"109185","DOI":"10.1016\/j.diabres.2021.109185","volume":"185","author":"M Hassanein","year":"2022","unstructured":"Hassanein M, Afandi B, Yakoob Ahmedani M et al (2022) Diabetes and Ramadan: practical guidelines 2021. Diabetes Res Clin Pract 185:109185. https:\/\/doi.org\/10.1016\/j.diabres.2021.109185","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"6833_CR97","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/jhn.13017","volume":"35","author":"CE Builes-Montano","year":"2022","unstructured":"Builes-Montano CE, Ortiz-Cano NA, Ramirez-Rincon A, Rojas-Henao NA (2022) Efficacy and safety of carbohydrate counting versus other forms of dietary advice in patients with type 1 diabetes mellitus: a systematic review and meta-analysis of randomised clinical trials. J Hum Nutr Diet 35(6):1030\u20131042. https:\/\/doi.org\/10.1111\/jhn.13017","journal-title":"J Hum Nutr Diet"},{"issue":"3","key":"6833_CR98","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1007\/s00125-016-4189-8","volume":"60","author":"H Tikkanen-Dolenc","year":"2017","unstructured":"Tikkanen-Dolenc H, Waden J, Forsblom C et al (2017) Frequent and intensive physical activity reduces risk of cardiovascular events in type 1 diabetes. Diabetologia 60(3):574\u2013580. https:\/\/doi.org\/10.1007\/s00125-016-4189-8","journal-title":"Diabetologia"},{"issue":"12","key":"6833_CR99","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.2337\/dc17-0615","volume":"40","author":"H Tikkanen-Dolenc","year":"2017","unstructured":"Tikkanen-Dolenc H, Waden J, Forsblom C et al (2017) Physical activity reduces risk of premature mortality in patients with type 1 diabetes with and without kidney disease. Diabetes Care 40(12):1727\u20131732. https:\/\/doi.org\/10.2337\/dc17-0615","journal-title":"Diabetes Care"},{"issue":"3","key":"6833_CR100","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s00125-011-2403-2","volume":"55","author":"M Chimen","year":"2012","unstructured":"Chimen M, Kennedy A, Nirantharakumar K, Pang TT, Andrews R, Narendran P (2012) What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. Diabetologia 55(3):542\u2013551. https:\/\/doi.org\/10.1007\/s00125-011-2403-2","journal-title":"Diabetologia"},{"issue":"6","key":"6833_CR101","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41574-023-00816-5","volume":"19","author":"D Tatovic","year":"2023","unstructured":"Tatovic D, Narendran P, Dayan CM (2023) A perspective on treating type 1 diabetes mellitus before insulin is needed. Nat Rev Endocrinol 19(6):361\u2013370. https:\/\/doi.org\/10.1038\/s41574-023-00816-5","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"6833_CR102","doi-asserted-by":"publisher","first-page":"e15415","DOI":"10.1111\/dme.15415","volume":"41","author":"D De Cock","year":"2024","unstructured":"De Cock D, Schreurs L, Steenackers N et al (2024) The effect of physical activity on glycaemic control in people with type 1 diabetes mellitus: a systematic literature review and meta-analysis. Diabet Med 41(10):e15415. https:\/\/doi.org\/10.1111\/dme.15415","journal-title":"Diabet Med"},{"issue":"5","key":"6833_CR103","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00592-019-01454-y","volume":"57","author":"H Tikkanen-Dolenc","year":"2020","unstructured":"Tikkanen-Dolenc H, Waden J, Forsblom C et al (2020) Frequent physical activity is associated with reduced risk of severe diabetic retinopathy in type 1 diabetes. Acta Diabetol 57(5):527\u2013534. https:\/\/doi.org\/10.1007\/s00592-019-01454-y","journal-title":"Acta Diabetol"},{"issue":"7","key":"6833_CR104","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1249\/01.MSS.0000074459.41029.75","volume":"35","author":"JW Lemaster","year":"2003","unstructured":"Lemaster JW, Reiber GE, Smith DG, Heagerty PJ, Wallace C (2003) Daily weight-bearing activity does not increase the risk of diabetic foot ulcers. Med Sci Sports Exerc 35(7):1093\u20131099. https:\/\/doi.org\/10.1249\/01.MSS.0000074459.41029.75","journal-title":"Med Sci Sports Exerc"},{"issue":"5","key":"6833_CR105","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S2213-8587(17)30014-1","volume":"5","author":"MC Riddell","year":"2017","unstructured":"Riddell MC, Gallen IW, Smart CE et al (2017) Exercise management in type 1 diabetes: a consensus statement. Lancet Diabetes Endocrinol 5(5):377\u2013390. https:\/\/doi.org\/10.1016\/S2213-8587(17)30014-1","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"6833_CR106","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/pedi.13452","volume":"23","author":"P Adolfsson","year":"2022","unstructured":"Adolfsson P, Taplin CE, Zaharieva DP et al (2022) ISPAD Clinical Practice Consensus Guidelines 2022: exercise in children and adolescents with diabetes. Pediatr Diabetes 23(8):1341\u20131372. https:\/\/doi.org\/10.1111\/pedi.13452","journal-title":"Pediatr Diabetes"},{"key":"6833_CR107","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2023.0293","author":"RT Zimmer","year":"2023","unstructured":"Zimmer RT, Auth A, Schierbauer J et al (2023) (Hybrid) closed-loop systems: from announced to unannounced exercise. Diabetes Technol Ther. https:\/\/doi.org\/10.1089\/dia.2023.0293","journal-title":"Diabetes Technol Ther"},{"key":"6833_CR108","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.sleep.2016.03.019","volume":"23","author":"S Reutrakul","year":"2016","unstructured":"Reutrakul S, Thakkinstian A, Anothaisintawee T et al (2016) Sleep characteristics in type 1 diabetes and associations with glycemic control: systematic review and meta-analysis. Sleep Med 23:26\u201345. https:\/\/doi.org\/10.1016\/j.sleep.2016.03.019","journal-title":"Sleep Med"},{"key":"6833_CR109","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/NSS.S152555","volume":"12","author":"MM Perfect","year":"2020","unstructured":"Perfect MM (2020) Sleep-related disorders in patients with type 1 diabetes mellitus: current insights. Nat Sci Sleep 12:101\u2013123. https:\/\/doi.org\/10.2147\/NSS.S152555","journal-title":"Nat Sci Sleep"},{"issue":"8","key":"6833_CR110","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1007\/s00125-011-2184-7","volume":"54","author":"M van Dijk","year":"2011","unstructured":"van Dijk M, Donga E, van Dijk JG et al (2011) Disturbed subjective sleep characteristics in adult patients with long-standing type 1 diabetes mellitus. Diabetologia 54(8):1967\u20131976. https:\/\/doi.org\/10.1007\/s00125-011-2184-7","journal-title":"Diabetologia"},{"key":"6833_CR111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diabres.2016.06.013","volume":"119","author":"H Denic-Roberts","year":"2016","unstructured":"Denic-Roberts H, Costacou T, Orchard TJ (2016) Subjective sleep disturbances and glycemic control in adults with long-standing type 1 diabetes: The Pittsburgh\u2019s Epidemiology of Diabetes Complications study. Diabetes Res Clin Pract 119:1\u201312. https:\/\/doi.org\/10.1016\/j.diabres.2016.06.013","journal-title":"Diabetes Res Clin Pract"},{"key":"6833_CR112","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/pdi.2253","volume":"37","author":"J Charlton","year":"2020","unstructured":"Charlton J, Gill J, Elliott L, Whittaker A, Farquharson B, Strachan MWJ (2020) A review of the challenges, glycaemic risks and self-care for people with type 1 diabetes when consuming alcoholic beverages. Practical Diabetes 37:7\u201312c. https:\/\/doi.org\/10.1002\/pdi.2253","journal-title":"Practical Diabetes"},{"issue":"1","key":"6833_CR113","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2337\/dc19-0365","volume":"43","author":"GL Kinney","year":"2020","unstructured":"Kinney GL, Akturk HK, Taylor DD, Foster NC, Shah VN (2020) Cannabis use is associated with increased risk for diabetic ketoacidosis in adults with type 1 diabetes: findings from the T1D exchange clinic registry. Diabetes Care 43(1):247\u2013249. https:\/\/doi.org\/10.2337\/dc19-0365","journal-title":"Diabetes Care"},{"issue":"3","key":"6833_CR114","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S2213-8587(19)30410-3","volume":"8","author":"A Pastor","year":"2020","unstructured":"Pastor A, Conn J, MacIsaac RJ, Bonomo Y (2020) Alcohol and illicit drug use in people with diabetes. Lancet Diabetes Endocrinol 8(3):239\u2013248. https:\/\/doi.org\/10.1016\/S2213-8587(19)30410-3","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"6833_CR115","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jcjd.2025.02.004","volume":"49","author":"KE Karakus","year":"2025","unstructured":"Karakus KE, Akturk HK (2025) Cannabis hyperemesis syndrome can mimic diabetic gastroparesis in cannabis users with type 1 diabetes. Can J Diabetes 49(3):218\u2013219. https:\/\/doi.org\/10.1016\/j.jcjd.2025.02.004","journal-title":"Can J Diabetes"},{"issue":"12","key":"6833_CR116","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1111\/dme.12491","volume":"31","author":"KD Barnard","year":"2014","unstructured":"Barnard KD, Dyson P, Sinclair JM et al (2014) Alcohol health literacy in young adults with type 1 diabetes and its impact on diabetes management. Diabet Med 31(12):1625\u20131630. https:\/\/doi.org\/10.1111\/dme.12491","journal-title":"Diabet Med"},{"issue":"2","key":"6833_CR117","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00592-010-0200-x","volume":"50","author":"PA Engler","year":"2013","unstructured":"Engler PA, Ramsey SE, Smith RJ (2013) Alcohol use of diabetes patients: the need for assessment and intervention. Acta Diabetol 50(2):93\u201399. https:\/\/doi.org\/10.1007\/s00592-010-0200-x","journal-title":"Acta Diabetol"},{"key":"6833_CR118","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.mvr.2014.01.002","volume":"92","author":"A Uruska","year":"2014","unstructured":"Uruska A, Araszkiewicz A, Uruski P, Zozulinska-Ziolkiewicz D (2014) Higher risk of microvascular complications in smokers with type 1 diabetes despite intensive insulin therapy. Microvasc Res 92:79\u201384. https:\/\/doi.org\/10.1016\/j.mvr.2014.01.002","journal-title":"Microvasc Res"},{"issue":"6","key":"6833_CR119","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1111\/dom.15531","volume":"26","author":"MAG Helmink","year":"2024","unstructured":"Helmink MAG, Hageman SHJ, Eliasson B et al (2024) Lifetime and 10-year cardiovascular risk prediction in individuals with type 1 diabetes: the LIFE-T1D model. Diabetes Obes Metab 26(6):2229\u20132238. https:\/\/doi.org\/10.1111\/dom.15531","journal-title":"Diabetes Obes Metab"},{"issue":"19","key":"6833_CR120","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1161\/CIRCULATIONAHA.115.017926","volume":"132","author":"A Pan","year":"2015","unstructured":"Pan A, Wang Y, Talaei M, Hu FB (2015) Relation of smoking with total mortality and cardiovascular events among patients with diabetes mellitus: a meta-analysis and systematic review. Circulation 132(19):1795\u20131804. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.017926","journal-title":"Circulation"},{"issue":"4","key":"6833_CR121","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1177\/1932296820922254","volume":"15","author":"MH Jensen","year":"2021","unstructured":"Jensen MH, Cichosz SL, Hirsch IB, Vestergaard P, Hejlesen O, Seto E (2021) Smoking is associated with increased risk of not achieving glycemic target, increased glycemic variability, and increased risk of hypoglycemia for people with type 1 diabetes. J Diabetes Sci Technol 15(4):827\u2013832. https:\/\/doi.org\/10.1177\/1932296820922254","journal-title":"J Diabetes Sci Technol"},{"issue":"5","key":"6833_CR122","doi-asserted-by":"publisher","first-page":"taae023","DOI":"10.1093\/jtm\/taae023","volume":"31","author":"C Tarlton","year":"2024","unstructured":"Tarlton C, James S, Dixson B, Craft J (2024) Travel health practices, behaviours and experiences of people living with type 1 diabetes. J Travel Med 31(5):taae023. https:\/\/doi.org\/10.1093\/jtm\/taae023","journal-title":"J Travel Med"},{"issue":"11","key":"6833_CR123","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.2337\/dci24-0068","volume":"47","author":"DJ Cox","year":"2024","unstructured":"Cox DJ, Frier BM, Bruggeman B et al (2024) Diabetes and driving: a statement of the American Diabetes Association. Diabetes Care 47(11):1889\u20131896. https:\/\/doi.org\/10.2337\/dci24-0068","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"6833_CR124","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.2337\/dc14-S112","volume":"37","author":"JE Anderson","year":"2014","unstructured":"American Diabetes Association, Anderson JE, Greene MA et al (2014) Diabetes and employment. Diabetes Care 37(Suppl 1):S112-117. https:\/\/doi.org\/10.2337\/dc14-S112","journal-title":"Diabetes Care"},{"key":"6833_CR125","doi-asserted-by":"publisher","unstructured":"Durrani T, East B, Fischer A et al (2026) Employment and diabetes: a statement of the American Diabetes Association. Diabetes Obes CardioMetabolic Care\u00a01(4):572\u2013581. https:\/\/doi.org\/10.2337\/doc25-0092","DOI":"10.2337\/doc25-0092"},{"issue":"7","key":"6833_CR126","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1037\/a0040388","volume":"71","author":"JS Gonzalez","year":"2016","unstructured":"Gonzalez JS, Tanenbaum ML, Commissariat PV (2016) Psychosocial factors in medication adherence and diabetes self-management: implications for research and practice. Am Psychol 71(7):539\u2013551. https:\/\/doi.org\/10.1037\/a0040388","journal-title":"Am Psychol"},{"issue":"7","key":"6833_CR127","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1037\/a0040408","volume":"71","author":"M de Groot","year":"2016","unstructured":"de Groot M, Golden SH, Wagner J (2016) Psychological conditions in adults with diabetes. Am Psychol 71(7):552\u2013562. https:\/\/doi.org\/10.1037\/a0040408","journal-title":"Am Psychol"},{"issue":"1","key":"6833_CR128","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dci20-0053","volume":"44","author":"F Hill-Briggs","year":"2020","unstructured":"Hill-Briggs F, Adler NE, Berkowitz SA et al (2020) Social determinants of health and diabetes: a scientific review. Diabetes Care 44(1):258\u2013279. https:\/\/doi.org\/10.2337\/dci20-0053","journal-title":"Diabetes Care"},{"issue":"6","key":"6833_CR129","doi-asserted-by":"publisher","first-page":"101486","DOI":"10.1016\/j.diabet.2023.101486","volume":"49","author":"S Franc","year":"2023","unstructured":"Franc S, Bensaid S, Schaepelynck P, Orlando L, Lopes P, Charpentier G (2023) Impact of chronic emotions and psychosocial stress on glycemic control in patients with type 1 diabetes. Heterogeneity of glycemic responses, biological mechanisms, and personalized medical treatment. Diabetes Metab 49(6):101486. https:\/\/doi.org\/10.1016\/j.diabet.2023.101486","journal-title":"Diabetes Metab"},{"issue":"7","key":"6833_CR130","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/dme.12245","volume":"30","author":"A Nicolucci","year":"2013","unstructured":"Nicolucci A, Kovacs BK, Holt RI et al (2013) Diabetes attitudes, wishes and needs second study (DAWN2): cross-national benchmarking of diabetes-related psychosocial outcomes for people with diabetes. Diabet Med 30(7):767\u2013777. https:\/\/doi.org\/10.1111\/dme.12245","journal-title":"Diabet Med"},{"issue":"4","key":"6833_CR131","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/dme.14216","volume":"37","author":"E van Duinkerken","year":"2020","unstructured":"van Duinkerken E, Snoek FJ, de Wit M (2020) The cognitive and psychological effects of living with type 1 diabetes: a narrative review. Diabet Med 37(4):555\u2013563. https:\/\/doi.org\/10.1111\/dme.14216","journal-title":"Diabet Med"},{"issue":"4","key":"6833_CR132","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jdiacomp.2015.01.012","volume":"29","author":"L Fisher","year":"2015","unstructured":"Fisher L, Polonsky WH, Hessler DM et al (2015) Understanding the sources of diabetes distress in adults with type 1 diabetes. J Diabetes Complications 29(4):572\u2013577. https:\/\/doi.org\/10.1016\/j.jdiacomp.2015.01.012","journal-title":"J Diabetes Complications"},{"issue":"8","key":"6833_CR133","doi-asserted-by":"publisher","first-page":"103112","DOI":"10.1016\/j.dsx.2024.103112","volume":"18","author":"A Housni","year":"2024","unstructured":"Housni A, Katz A, Kichler JC, Nakhla M, Secours L, Brazeau AS (2024) Predictors of stigma perception by people with type 1 diabetes: a cross-sectional analysis of the BETTER registry. Diabetes Metab Syndr 18(8):103112. https:\/\/doi.org\/10.1016\/j.dsx.2024.103112","journal-title":"Diabetes Metab Syndr"},{"issue":"9","key":"6833_CR134","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/dme.13381","volume":"34","author":"DM Hessler","year":"2017","unstructured":"Hessler DM, Fisher L, Polonsky WH et al (2017) Diabetes distress is linked with worsening diabetes management over time in adults with Type 1 diabetes. Diabet Med 34(9):1228\u20131234. https:\/\/doi.org\/10.1111\/dme.13381","journal-title":"Diabet Med"},{"key":"6833_CR135","unstructured":"Holt RIG (2005) Diabetes and depression. In: Feingold KR, Ahmed SF, Anawalt B et al (eds) Endotext. MDText.com, South Dartmouth, MA, USA"},{"issue":"8","key":"6833_CR136","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jdiacomp.2019.04.013","volume":"33","author":"G Nefs","year":"2019","unstructured":"Nefs G, Hendrieckx C, Reddy P et al (2019) Comorbid elevated symptoms of anxiety and depression in adults with type 1 or type 2 diabetes: results from the International Diabetes MILES Study. J Diabetes Complications 33(8):523\u2013529. https:\/\/doi.org\/10.1016\/j.jdiacomp.2019.04.013","journal-title":"J Diabetes Complications"},{"issue":"6","key":"6833_CR137","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S2213-8587(15)00135-7","volume":"3","author":"FJ Snoek","year":"2015","unstructured":"Snoek FJ, Bremmer MA, Hermanns N (2015) Constructs of depression and distress in diabetes: time for an appraisal. Lancet Diabetes Endocrinol 3(6):450\u2013460. https:\/\/doi.org\/10.1016\/S2213-8587(15)00135-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"6833_CR138","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/dme.14227","volume":"37","author":"F Pouwer","year":"2020","unstructured":"Pouwer F, Schram MT, Iversen MM, Nouwen A, Holt RIG (2020) How 25 years of psychosocial research has contributed to a better understanding of the links between depression and diabetes. Diabet Med 37(3):383\u2013392. https:\/\/doi.org\/10.1111\/dme.14227","journal-title":"Diabet Med"},{"issue":"1","key":"6833_CR139","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/14768320701205218","volume":"23","author":"S Sultan","year":"2008","unstructured":"Sultan S, Epel E, Sachon C, Vaillant G, Hartemann-Heurtier A (2008) A longitudinal study of coping, anxiety and glycemic control in adults with type 1 diabetes. Psychol Health 23(1):73\u201389. https:\/\/doi.org\/10.1080\/14768320701205218","journal-title":"Psychol Health"},{"issue":"1","key":"6833_CR140","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.pec.2007.05.003","volume":"68","author":"D Wild","year":"2007","unstructured":"Wild D, von Maltzahn R, Brohan E, Christensen T, Clauson P, Gonder-Frederick L (2007) A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education. Patient Educ Couns 68(1):10\u201315. https:\/\/doi.org\/10.1016\/j.pec.2007.05.003","journal-title":"Patient Educ Couns"},{"issue":"1","key":"6833_CR141","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/bjhp.12697","volume":"29","author":"V McKechnie","year":"2024","unstructured":"McKechnie V, Oliver N, Amiel SA, Fox JRE (2024) Hyperglycaemia aversion in type 1 diabetes: a grounded theory study. Br J Health Psychol 29(1):254\u2013271. https:\/\/doi.org\/10.1111\/bjhp.12697","journal-title":"Br J Health Psychol"},{"issue":"6","key":"6833_CR142","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1007\/s00125-022-05679-5","volume":"65","author":"P Jacob","year":"2022","unstructured":"Jacob P, Potts L, Maclean RH et al (2022) Characteristics of adults with type 1 diabetes and treatment-resistant problematic hypoglycaemia: a baseline analysis from the HARPdoc RCT. Diabetologia 65(6):936\u2013948. https:\/\/doi.org\/10.1007\/s00125-022-05679-5","journal-title":"Diabetologia"},{"issue":"3","key":"6833_CR143","doi-asserted-by":"publisher","first-page":"e473","DOI":"10.1002\/edm2.473","volume":"7","author":"YE Dean","year":"2024","unstructured":"Dean YE, Motawea KR, Aslam M et al (2024) Association between type 1 diabetes mellitus and eating disorders: a systematic review and meta-analysis. Endocrinol Diabetes Metab 7(3):e473. https:\/\/doi.org\/10.1002\/edm2.473","journal-title":"Endocrinol Diabetes Metab"},{"issue":"4","key":"6833_CR144","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s00125-024-06346-7","volume":"68","author":"L Hirvela","year":"2025","unstructured":"Hirvela L, Haukka J, Keski-Rahkonen A, Sipila PN (2025) Eating disorders among people with and without type 1 diabetes: incidence and treatment in a nationwide population-based cohort. Diabetologia 68(4):766\u2013777. https:\/\/doi.org\/10.1007\/s00125-024-06346-7","journal-title":"Diabetologia"},{"key":"6833_CR145","doi-asserted-by":"publisher","first-page":"109783","DOI":"10.1016\/j.diabres.2022.109783","volume":"185","author":"G Goddard","year":"2022","unstructured":"Goddard G, Oxlad M (2022) Caring for individuals with Type 1 Diabetes Mellitus who restrict and omit insulin for weight control: evidence-based guidance for healthcare professionals. Diabetes Res Clin Pract 185:109783. https:\/\/doi.org\/10.1016\/j.diabres.2022.109783","journal-title":"Diabetes Res Clin Pract"},{"key":"6833_CR146","doi-asserted-by":"publisher","first-page":"982696","DOI":"10.3389\/fpsyt.2022.982696","volume":"13","author":"XN Xie","year":"2022","unstructured":"Xie XN, Lei X, Xiao CY, Li YM, Lei XY (2022) Association between type 1 diabetes and neurodevelopmental disorders in children and adolescents: a systematic review and meta-analysis. Front Psychiatry 13:982696. https:\/\/doi.org\/10.3389\/fpsyt.2022.982696","journal-title":"Front Psychiatry"},{"issue":"11","key":"6833_CR147","doi-asserted-by":"publisher","first-page":"e4459","DOI":"10.1210\/clinem\/dgab467","volume":"106","author":"S Liu","year":"2021","unstructured":"Liu S, Kuja-Halkola R, Larsson H et al (2021) Neurodevelopmental disorders, glycemic control, and diabetic complications in type 1 diabetes: a nationwide cohort study. J Clin Endocrinol Metab 106(11):e4459\u2013e4470. https:\/\/doi.org\/10.1210\/clinem\/dgab467","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"6833_CR148","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S2213-8587(21)00086-3","volume":"9","author":"AM Jacobson","year":"2021","unstructured":"Jacobson AM, Ryan CM, Braffett BH et al (2021) Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC Study. Lancet Diabetes Endocrinol 9(7):436\u2013445. https:\/\/doi.org\/10.1016\/S2213-8587(21)00086-3","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl 1","key":"6833_CR149","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/dom.15471","volume":"26","author":"N Hermanns","year":"2024","unstructured":"Hermanns N, Kulzer B, Ehrmann D (2024) Person-reported outcomes in diabetes care: what are they and why are they so important? Diabetes Obes Metab 26(Suppl 1):30\u201345. https:\/\/doi.org\/10.1111\/dom.15471","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"6833_CR150","doi-asserted-by":"publisher","first-page":"e15332","DOI":"10.1111\/dme.15332","volume":"41","author":"K Barnard-Kelly","year":"2024","unstructured":"Barnard-Kelly K, Marrero D, de Wit M et al (2024) Towards the standardisation of adult person-reported outcome domains in diabetes research: a consensus statement development panel. Diabet Med 41(8):e15332. https:\/\/doi.org\/10.1111\/dme.15332","journal-title":"Diabet Med"},{"issue":"3","key":"6833_CR151","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2337\/dc10-1552","volume":"34","author":"FJ Snoek","year":"2011","unstructured":"Snoek FJ, Kersch NY, Eldrup E et al (2011) Monitoring of Individual Needs in Diabetes (MIND): baseline data from the Cross-National Diabetes Attitudes, Wishes, and Needs (DAWN) MIND study. Diabetes Care 34(3):601\u2013603. https:\/\/doi.org\/10.2337\/dc10-1552","journal-title":"Diabetes Care"},{"issue":"11","key":"6833_CR152","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.2337\/diacare.24.11.1929","volume":"24","author":"F Pouwer","year":"2001","unstructured":"Pouwer F, Snoek FJ, van der Ploeg HM, Ader HJ, Heine RJ (2001) Monitoring of psychological well-being in outpatients with diabetes: effects on mood, HbA(1c), and the patient\u2019s evaluation of the quality of diabetes care: a randomized controlled trial. Diabetes Care 24(11):1929\u20131935. https:\/\/doi.org\/10.2337\/diacare.24.11.1929","journal-title":"Diabetes Care"},{"issue":"2","key":"6833_CR153","doi-asserted-by":"publisher","first-page":"e14671","DOI":"10.1111\/dme.14671","volume":"39","author":"M Beran","year":"2022","unstructured":"Beran M, Muzambi R, Geraets A et al (2022) The bidirectional longitudinal association between depressive symptoms and HbA(1c): a systematic review and meta-analysis. Diabet Med 39(2):e14671. https:\/\/doi.org\/10.1111\/dme.14671","journal-title":"Diabet Med"},{"issue":"4","key":"6833_CR154","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/imj.13375","volume":"47","author":"H d'Emden","year":"2017","unstructured":"d\u2019Emden H, McDermott B, D\u2019Silva N et al (2017) Psychosocial screening and management of young people aged 18\u201325 years with diabetes. Intern Med J 47(4):415\u2013423. https:\/\/doi.org\/10.1111\/imj.13375","journal-title":"Intern Med J"},{"key":"6833_CR155","doi-asserted-by":"publisher","first-page":"107933","DOI":"10.1016\/j.pec.2023.107933","volume":"116","author":"K Hamilton","year":"2023","unstructured":"Hamilton K, Forde R, Due-Christensen M et al (2023) Which diabetes specific patient reported outcomes should be measured in routine care? A systematic review to inform a core outcome set for adults with Type 1 and 2 diabetes mellitus: the European Health Outcomes Observatory (H2O) programme. Patient Educ Couns 116:107933. https:\/\/doi.org\/10.1016\/j.pec.2023.107933","journal-title":"Patient Educ Couns"},{"issue":"12","key":"6833_CR156","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1111\/dme.14286","volume":"37","author":"J Nano","year":"2020","unstructured":"Nano J, Carinci F, Okunade O et al (2020) A standard set of person-centred outcomes for diabetes mellitus: results of an international and unified approach. Diabet Med 37(12):2009\u20132018. https:\/\/doi.org\/10.1111\/dme.14286","journal-title":"Diabet Med"},{"issue":"4","key":"6833_CR157","doi-asserted-by":"publisher","first-page":"107522","DOI":"10.1016\/j.jdiacomp.2020.107522","volume":"34","author":"KM Pursey","year":"2020","unstructured":"Pursey KM, Hart M, Jenkins L, McEvoy M, Smart CE (2020) Screening and identification of disordered eating in people with type 1 diabetes: a systematic review. J Diabetes Complications 34(4):107522. https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107522","journal-title":"J Diabetes Complications"},{"issue":"12","key":"6833_CR158","doi-asserted-by":"publisher","first-page":"e15446","DOI":"10.1111\/dme.15446","volume":"41","author":"L Fisher","year":"2024","unstructured":"Fisher L, Guzman S, Polonsky W, Hessler D (2024) Bringing the assessment and treatment of diabetes distress into the real world of clinical care: time for a shift in perspective. Diabet Med 41(12):e15446. https:\/\/doi.org\/10.1111\/dme.15446","journal-title":"Diabet Med"},{"issue":"12","key":"6833_CR159","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.2337\/dc16-2053","volume":"39","author":"D Young-Hyman","year":"2016","unstructured":"Young-Hyman D, de Groot M, Hill-Briggs F, Gonzalez JS, Hood K, Peyrot M (2016) Psychosocial care for people with diabetes: a position statement of the American Diabetes Association. Diabetes Care 39(12):2126\u20132140. https:\/\/doi.org\/10.2337\/dc16-2053","journal-title":"Diabetes Care"},{"issue":"5","key":"6833_CR160","doi-asserted-by":"publisher","first-page":"e15312","DOI":"10.1111\/dme.15312","volume":"41","author":"FJ Snoek","year":"2024","unstructured":"Snoek FJ, Anarte-Ortiz MT, Anderbro T et al (2024) Roles and competencies of the clinical psychologist in adult diabetes care-A consensus report. Diabet Med 41(5):e15312. https:\/\/doi.org\/10.1111\/dme.15312","journal-title":"Diabet Med"},{"key":"6833_CR161","doi-asserted-by":"publisher","first-page":"e52923","DOI":"10.2196\/52923","volume":"9","author":"J Embaye","year":"2024","unstructured":"Embaye J, de Wit M, Snoek F (2024) A self-guided web-based app (MyDiaMate) for enhancing mental health in adults with type 1 diabetes: insights from a real-world study in the Netherlands. JMIR Diabetes 9:e52923. https:\/\/doi.org\/10.2196\/52923","journal-title":"JMIR Diabetes"},{"issue":"1","key":"6833_CR162","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11892-024-01560-4","volume":"25","author":"TI Yakubu","year":"2024","unstructured":"Yakubu TI, Pawer S, West NC, Tang TS, Gorges M (2024) Impact of digitally enabled peer support interventions on diabetes distress and depressive symptoms in people living with type 1 diabetes: a systematic review. Curr Diab Rep 25(1):1. https:\/\/doi.org\/10.1007\/s11892-024-01560-4","journal-title":"Curr Diab Rep"},{"key":"6833_CR163","doi-asserted-by":"publisher","first-page":"109965","DOI":"10.1016\/j.diabres.2022.109965","volume":"189","author":"Y Li","year":"2022","unstructured":"Li Y, Storch EA, Ferguson S, Li L, Buys N, Sun J (2022) The efficacy of cognitive behavioral therapy-based intervention on patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 189:109965. https:\/\/doi.org\/10.1016\/j.diabres.2022.109965","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"6833_CR164","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s13300-023-01513-2","volume":"15","author":"O Diribe","year":"2024","unstructured":"Diribe O, Palmer K, Kennedy A et al (2024) A systematic literature review of psychological interventions for adults with type 1 diabetes. Diabetes Ther 15(2):367\u2013380. https:\/\/doi.org\/10.1007\/s13300-023-01513-2","journal-title":"Diabetes Ther"},{"issue":"28","key":"6833_CR165","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta24280","volume":"24","author":"K Winkley","year":"2020","unstructured":"Winkley K, Upsher R, Stahl D et al (2020) Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review. Health Technol Assess 24(28):1\u2013232. https:\/\/doi.org\/10.3310\/hta24280","journal-title":"Health Technol Assess"},{"issue":"2","key":"6833_CR166","doi-asserted-by":"publisher","first-page":"e01981","DOI":"10.1002\/brb3.1981","volume":"11","author":"C van der Feltz-Cornelis","year":"2021","unstructured":"van der Feltz-Cornelis C, Allen SF, Holt RIG, Roberts R, Nouwen A, Sartorius N (2021) Treatment for comorbid depressive disorder or subthreshold depression in diabetes mellitus: Systematic review and meta-analysis. Brain Behav 11(2):e01981. https:\/\/doi.org\/10.1002\/brb3.1981","journal-title":"Brain Behav"},{"key":"6833_CR167","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/1472-6963-10-235","volume":"10","author":"KM van Steenbergen-Weijenburg","year":"2010","unstructured":"van Steenbergen-Weijenburg KM, de Vroege L, Ploeger RR et al (2010) Validation of the PHQ-9 as a screening instrument for depression in diabetes patients in specialized outpatient clinics. BMC Health Serv Res 10:235. https:\/\/doi.org\/10.1186\/1472-6963-10-235","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"6833_CR168","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.eurpsy.2009.01.005","volume":"24","author":"M De Hert","year":"2009","unstructured":"De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Moller HJ (2009) Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 24(6):412\u2013424. https:\/\/doi.org\/10.1016\/j.eurpsy.2009.01.005","journal-title":"Eur Psychiatry"},{"issue":"7","key":"6833_CR169","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1089\/dia.2024.0599","volume":"27","author":"EC Rizos","year":"2025","unstructured":"Rizos EC, Markozannes G, Charitakis N et al (2025) Continuous glucose monitoring in type 1 diabetes, type 2 diabetes, and diabetes during pregnancy: a systematic review with meta-analysis of randomized controlled trials. Diabetes Technol Ther 27(7):537\u2013552. https:\/\/doi.org\/10.1089\/dia.2024.0599","journal-title":"Diabetes Technol Ther"},{"issue":"23","key":"6833_CR170","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1001\/jama.2020.6928","volume":"323","author":"RE Pratley","year":"2020","unstructured":"Pratley RE, Kanapka LG, Rickels MR et al (2020) Effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes: a randomized clinical trial. JAMA 323(23):2397\u20132406. https:\/\/doi.org\/10.1001\/jama.2020.6928","journal-title":"JAMA"},{"issue":"11","key":"6833_CR171","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S2213-8587(16)30193-0","volume":"4","author":"CA van Beers","year":"2016","unstructured":"van Beers CA, DeVries JH, Kleijer SJ et al (2016) Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol 4(11):893\u2013902. https:\/\/doi.org\/10.1016\/S2213-8587(16)30193-0","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"6833_CR172","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1177\/19322968241250357","volume":"19","author":"DC Klonoff","year":"2025","unstructured":"Klonoff DC, Gabbay M, Moon SJ, Wilmot EG (2025) Importance of FDA-integrated continuous glucose monitors to ensure accuracy of continuous glucose monitoring. J Diabetes Sci Technol 19(5):1392\u20131399. https:\/\/doi.org\/10.1177\/19322968241250357","journal-title":"J Diabetes Sci Technol"},{"issue":"3","key":"6833_CR173","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/dom.16153","volume":"27","author":"C Mathieu","year":"2025","unstructured":"Mathieu C, Irace C, Wilmot EG et al (2025) Minimum expectations for market authorization of continuous glucose monitoring devices in Europe-\u2019eCGM\u2019 compliance status. Diabetes Obes Metab 27(3):1025\u20131031. https:\/\/doi.org\/10.1111\/dom.16153","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"6833_CR174","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.2337\/dc23-2332","volume":"47","author":"P Divilly","year":"2024","unstructured":"Divilly P, Martine-Edith G, Zaremba N et al (2024) Relationship between sensor-detected hypoglycemia and patient-reported hypoglycemia in people with type 1 and insulin-treated type 2 diabetes: the hypo-METRICS study. Diabetes Care 47(10):1769\u20131777. https:\/\/doi.org\/10.2337\/dc23-2332","journal-title":"Diabetes Care"},{"issue":"10","key":"6833_CR175","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.2337\/dci23-0048","volume":"46","author":"DB Sacks","year":"2023","unstructured":"Sacks DB, Arnold M, Bakris GL et al (2023) Executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 46(10):1740\u20131746. https:\/\/doi.org\/10.2337\/dci23-0048","journal-title":"Diabetes Care"},{"issue":"Suppl 7","key":"6833_CR176","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/dom.15921","volume":"26","author":"YW Kong","year":"2024","unstructured":"Kong YW, Morrison D, Lu JC, Lee MH, Jenkins AJ, O\u2019Neal DN (2024) Continuous ketone monitoring: exciting implications for clinical practice. Diabetes Obes Metab 26(Suppl 7):47\u201358. https:\/\/doi.org\/10.1111\/dom.15921","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"6833_CR177","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S2213-8587(25)00331-6","volume":"14","author":"K Dhatariya","year":"2026","unstructured":"Dhatariya K, Bergenstal RM, Al-Sofiani M et al (2026) Continuous ketone monitoring for people with diabetes: international expert recommendations on the application of a new technology. Lancet Diabetes Endocrinol 14(1):82\u201392. https:\/\/doi.org\/10.1016\/S2213-8587(25)00331-6","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"6833_CR178","doi-asserted-by":"publisher","first-page":"460","DOI":"10.2337\/dc23-1177","volume":"47","author":"V Tozzo","year":"2024","unstructured":"Tozzo V, Genco M, Omololu SO et al (2024) Estimating glycemia from HbA1c and CGM: analysis of accuracy and sources of discrepancy. Diabetes Care 47(3):460\u2013466. https:\/\/doi.org\/10.2337\/dc23-1177","journal-title":"Diabetes Care"},{"issue":"8","key":"6833_CR179","doi-asserted-by":"publisher","first-page":"994","DOI":"10.2337\/dc17-0636","volume":"40","author":"RW Beck","year":"2017","unstructured":"Beck RW, Connor CG, Mullen DM, Wesley DM, Bergenstal RM (2017) The fallacy of average: how using HbA(1c) alone to assess glycemic control can be misleading. Diabetes Care 40(8):994\u2013999. https:\/\/doi.org\/10.2337\/dc17-0636","journal-title":"Diabetes Care"},{"issue":"4","key":"6833_CR180","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1177\/1932296818822496","volume":"13","author":"RW Beck","year":"2019","unstructured":"Beck RW, Bergenstal RM, Cheng P et al (2019) The relationships between time in range, hyperglycemia metrics, and HbA1c. J Diabetes Sci Technol 13(4):614\u2013626. https:\/\/doi.org\/10.1177\/1932296818822496","journal-title":"J Diabetes Sci Technol"},{"issue":"6","key":"6833_CR181","doi-asserted-by":"publisher","first-page":"e2221","DOI":"10.1210\/clinem\/dgac034","volume":"107","author":"M Yapanis","year":"2022","unstructured":"Yapanis M, James S, Craig ME, O\u2019Neal D, Ekinci EI (2022) Complications of diabetes and metrics of glycemic management derived from continuous glucose monitoring. J Clin Endocrinol Metab 107(6):e2221\u2013e2236. https:\/\/doi.org\/10.1210\/clinem\/dgac034","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"6833_CR182","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.2337\/dc15-1188","volume":"38","author":"C Gorst","year":"2015","unstructured":"Gorst C, Kwok CS, Aslam S et al (2015) Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis. Diabetes Care 38(12):2354\u20132369. https:\/\/doi.org\/10.2337\/dc15-1188","journal-title":"Diabetes Care"},{"issue":"5","key":"6833_CR183","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1210\/endrev\/bnaa015","volume":"41","author":"IB Hirsch","year":"2020","unstructured":"Hirsch IB, Juneja R, Beals JM, Antalis CJ, Wright EE (2020) The evolution of insulin and how it informs therapy and treatment choices. Endocr Rev 41(5):733\u2013755. https:\/\/doi.org\/10.1210\/endrev\/bnaa015","journal-title":"Endocr Rev"},{"issue":"10413","key":"6833_CR184","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/S0140-6736(23)02179-7","volume":"402","author":"D Russell-Jones","year":"2023","unstructured":"Russell-Jones D, Babazono T, Cailleteau R et al (2023) Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial. Lancet 402(10413):1636\u20131647. https:\/\/doi.org\/10.1016\/S0140-6736(23)02179-7","journal-title":"Lancet"},{"issue":"10458","key":"6833_CR185","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/S0140-6736(24)01804-X","volume":"404","author":"RM Bergenstal","year":"2024","unstructured":"Bergenstal RM, Weinstock RS, Mathieu C et al (2024) Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial. Lancet 404(10458):1132\u20131142. https:\/\/doi.org\/10.1016\/S0140-6736(24)01804-X","journal-title":"Lancet"},{"key":"6833_CR186","doi-asserted-by":"publisher","first-page":"827484","DOI":"10.3389\/fendo.2022.827484","volume":"13","author":"M Masierek","year":"2022","unstructured":"Masierek M, Nabrdalik K, Janota O, Kwiendacz H, Macherski M, Gumprecht J (2022) The review of insulin pens-past, present, and look to the future. Front Endocrinol (Lausanne) 13:827484. https:\/\/doi.org\/10.3389\/fendo.2022.827484","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"6833_CR187","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1185\/03007995.2010.481203","volume":"26","author":"MA Gibney","year":"2010","unstructured":"Gibney MA, Arce CH, Byron KJ, Hirsch LJ (2010) Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Curr Med Res Opin 26(6):1519\u20131530. https:\/\/doi.org\/10.1185\/03007995.2010.481203","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"6833_CR188","doi-asserted-by":"publisher","first-page":"995","DOI":"10.2337\/dc23-2176","volume":"47","author":"TPA Danne","year":"2024","unstructured":"Danne TPA, Joubert M, Hartvig NV, Kaas A, Knudsen NN, Mader JK (2024) Association between treatment adherence and continuous glucose monitoring outcomes in people with diabetes using smart insulin pens in a real-world setting. Diabetes Care 47(6):995\u20131003. https:\/\/doi.org\/10.2337\/dc23-2176","journal-title":"Diabetes Care"},{"issue":"1","key":"6833_CR189","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/dom.15316","volume":"26","author":"J Hellman","year":"2024","unstructured":"Hellman J, Hartvig NV, Kaas A, Moller JB, Sorensen MR, Jendle J (2024) Associations of bolus insulin injection frequency and smart pen engagement with glycaemic control in people living with type 1 diabetes. Diabetes Obes Metab 26(1):301\u2013310. https:\/\/doi.org\/10.1111\/dom.15316","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"6833_CR190","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1089\/dia.2023.0365","volume":"26","author":"J MacLeod","year":"2024","unstructured":"MacLeod J, Im GH, Smith M, Vigersky RA (2024) Shining the spotlight on multiple daily insulin therapy: real-world evidence of the InPen smart insulin pen. Diabetes Technol Ther 26(1):33\u201339. https:\/\/doi.org\/10.1089\/dia.2023.0365","journal-title":"Diabetes Technol Ther"},{"issue":"10","key":"6833_CR191","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1089\/dia.2019.0411","volume":"22","author":"P Adolfsson","year":"2020","unstructured":"Adolfsson P, Hartvig NV, Kaas A, Moller JB, Hellman J (2020) Increased time in range and fewer missed bolus injections after introduction of a smart connected insulin pen. Diabetes Technol Ther 22(10):709\u2013718. https:\/\/doi.org\/10.1089\/dia.2019.0411","journal-title":"Diabetes Technol Ther"},{"issue":"3","key":"6833_CR192","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1177\/1932296820951225","volume":"16","author":"R Harbison","year":"2022","unstructured":"Harbison R, Hecht M, MacLeod J (2022) Building a data-driven multiple daily insulin therapy model using smart insulin pens. J Diabetes Sci Technol 16(3):610\u2013616. https:\/\/doi.org\/10.1177\/1932296820951225","journal-title":"J Diabetes Sci Technol"},{"issue":"10","key":"6833_CR193","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1007\/s00125-024-06165-w","volume":"67","author":"CK Boughton","year":"2024","unstructured":"Boughton CK, Hovorka R (2024) The role of automated insulin delivery technology in diabetes. Diabetologia 67(10):2034\u20132044. https:\/\/doi.org\/10.1007\/s00125-024-06165-w","journal-title":"Diabetologia"},{"issue":"6","key":"6833_CR194","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s13300-020-00823-z","volume":"11","author":"J Kesavadev","year":"2020","unstructured":"Kesavadev J, Srinivasan S, Saboo B, Krishna BM, Krishnan G (2020) The Do-It-Yourself artificial pancreas: a comprehensive review. Diabetes Ther 11(6):1217\u20131235. https:\/\/doi.org\/10.1007\/s13300-020-00823-z","journal-title":"Diabetes Ther"},{"issue":"4","key":"6833_CR195","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/MOT.0000000000000786","volume":"25","author":"CK Boughton","year":"2020","unstructured":"Boughton CK, Hovorka R (2020) The artificial pancreas. Curr Opin Organ Transplant 25(4):336\u2013342. https:\/\/doi.org\/10.1097\/MOT.0000000000000786","journal-title":"Curr Opin Organ Transplant"},{"issue":"6","key":"6833_CR196","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s40262-016-0473-5","volume":"56","author":"T Heise","year":"2017","unstructured":"Heise T, Stender-Petersen K, Hovelmann U et al (2017) Pharmacokinetic and pharmacodynamic properties of faster-acting insulin aspart versus insulin aspart across a clinically relevant dose range in subjects with type 1 diabetes mellitus. Clin Pharmacokinet 56(6):649\u2013660. https:\/\/doi.org\/10.1007\/s40262-016-0473-5","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"6833_CR197","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/dom.12856","volume":"19","author":"C Kapitza","year":"2017","unstructured":"Kapitza C, Nowotny I, Lehmann A et al (2017) Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes. Diabetes Obes Metab 19(5):622\u2013627. https:\/\/doi.org\/10.1111\/dom.12856","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"6833_CR198","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2337\/dc24-1832","volume":"48","author":"IB Hirsch","year":"2025","unstructured":"Hirsch IB, Beck RW, Marak MC et al (2025) A randomized trial comparing inhaled insulin plus basal insulin versus usual care in adults with type 1 diabetes. Diabetes Care 48(3):353\u2013360. https:\/\/doi.org\/10.2337\/dc24-1832","journal-title":"Diabetes Care"},{"issue":"3","key":"6833_CR199","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1089\/dia.2024.0582","volume":"27","author":"RW Beck","year":"2025","unstructured":"Beck RW, Bailey RJ, Klein KR et al (2025) Inhaled technosphere insulin plus insulin degludec for adults with type 1 diabetes: the INHALE-3 extension study. Diabetes Technol Ther 27(3):170\u2013178. https:\/\/doi.org\/10.1089\/dia.2024.0582","journal-title":"Diabetes Technol Ther"},{"issue":"10","key":"6833_CR200","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s40261-020-00958-8","volume":"40","author":"JB McGill","year":"2020","unstructured":"McGill JB, Peters A, Buse JB et al (2020) Comprehensive pulmonary safety review of inhaled technosphere((R)) insulin in patients with diabetes mellitus. Clin Drug Investig 40(10):973\u2013983. https:\/\/doi.org\/10.1007\/s40261-020-00958-8","journal-title":"Clin Drug Investig"},{"issue":"5","key":"6833_CR201","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S2213-8587(14)70035-X","volume":"2","author":"NA Spaan","year":"2014","unstructured":"Spaan NA, Teplova AE, Renard E, Spaan JA (2014) Implantable insulin pumps: an effective option with restricted dissemination. Lancet Diabetes Endocrinol 2(5):358\u2013360. https:\/\/doi.org\/10.1016\/S2213-8587(14)70035-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6833_CR202","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1472-6823-14-30","volume":"14","author":"PR van Dijk","year":"2014","unstructured":"van Dijk PR, Logtenberg SJ, Groenier KH, Gans RO, Kleefstra N, Bilo HJ (2014) Continuous intraperitoneal insulin infusion in type 1 diabetes: a 6-year post-trial follow-up. BMC Endocr Disord 14:30. https:\/\/doi.org\/10.1186\/1472-6823-14-30","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"6833_CR203","doi-asserted-by":"publisher","first-page":"026105","DOI":"10.1063\/5.0145446","volume":"7","author":"A Dalla Libera","year":"2023","unstructured":"Dalla Libera A, Toffanin C, Drecogna M, Galderisi A, Pillonetto G, Cobelli C (2023) In silico design and validation of a time-varying PID controller for an artificial pancreas with intraperitoneal insulin delivery and glucose sensing. APL Bioeng 7(2):026105. https:\/\/doi.org\/10.1063\/5.0145446","journal-title":"APL Bioeng"},{"issue":"6","key":"6833_CR204","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1177\/19322968231187661","volume":"17","author":"T Tian","year":"2023","unstructured":"Tian T, Aaron RE, Huang J et al (2023) Lipohypertrophy and insulin: an update from the Diabetes Technology Society. J Diabetes Sci Technol 17(6):1711\u20131721. https:\/\/doi.org\/10.1177\/19322968231187661","journal-title":"J Diabetes Sci Technol"},{"issue":"5","key":"6833_CR205","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1089\/dia.2023.0491","volume":"26","author":"JK Mader","year":"2024","unstructured":"Mader JK, Fornengo R, Hassoun A et al (2024) Relationship between lipohypertrophy, glycemic control, and insulin dosing: a systematic meta-analysis. Diabetes Technol Ther 26(5):351\u2013362. https:\/\/doi.org\/10.1089\/dia.2023.0491","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"6833_CR206","doi-asserted-by":"publisher","first-page":"e14672","DOI":"10.1111\/dme.14672","volume":"39","author":"N Bochanen","year":"2022","unstructured":"Bochanen N, Decochez K, Heleu E et al (2022) Lipohypertrophy Monitoring Study (LIMO): effect of single use of 4 mm pen needles combined with education on injection site rotation on glycaemic control: confirmation of an unpleasant truth. Diabet Med 39(1):e14672. https:\/\/doi.org\/10.1111\/dme.14672","journal-title":"Diabet Med"},{"issue":"8","key":"6833_CR207","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1007\/s00125-022-05710-9","volume":"65","author":"A Sola-Gazagnes","year":"2022","unstructured":"Sola-Gazagnes A, Pecquet C, Berre S et al (2022) Insulin allergy: a diagnostic and therapeutic strategy based on a retrospective cohort and a case-control study. Diabetologia 65(8):1278\u20131290. https:\/\/doi.org\/10.1007\/s00125-022-05710-9","journal-title":"Diabetologia"},{"issue":"4","key":"6833_CR208","doi-asserted-by":"publisher","first-page":"e70060","DOI":"10.1002\/edm2.70060","volume":"8","author":"MM Masouri","year":"2025","unstructured":"Masouri MM, Ebrahimi R, Noori S (2025) An updated systematic review and meta-analysis on the efficacy and safety of metformin as add-on therapy to insulin in patients with type 1 diabetes. Endocrinol Diabetes Metab 8(4):e70060. https:\/\/doi.org\/10.1002\/edm2.70060","journal-title":"Endocrinol Diabetes Metab"},{"issue":"8","key":"6833_CR209","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S2213-8587(17)30194-8","volume":"5","author":"JR Petrie","year":"2017","unstructured":"Petrie JR, Chaturvedi N, Ford I et al (2017) Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5(8):597\u2013609. https:\/\/doi.org\/10.1016\/S2213-8587(17)30194-8","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"6833_CR210","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s001250050646","volume":"40","author":"MF Kong","year":"1997","unstructured":"Kong MF, King P, Macdonald IA et al (1997) Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia 40(1):82\u201388. https:\/\/doi.org\/10.1007\/s001250050646","journal-title":"Diabetologia"},{"issue":"5","key":"6833_CR211","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s001250050949","volume":"41","author":"MF Kong","year":"1998","unstructured":"Kong MF, Stubbs TA, King P et al (1998) The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia 41(5):577\u2013583. https:\/\/doi.org\/10.1007\/s001250050949","journal-title":"Diabetologia"},{"issue":"5","key":"6833_CR212","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1053\/meta.2002.32022","volume":"51","author":"MS Fineman","year":"2002","unstructured":"Fineman MS, Koda JE, Shen LZ et al (2002) The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism 51(5):636\u2013641. https:\/\/doi.org\/10.1053\/meta.2002.32022","journal-title":"Metabolism"},{"issue":"5","key":"6833_CR213","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1007\/s00125-005-1732-4","volume":"48","author":"I Chapman","year":"2005","unstructured":"Chapman I, Parker B, Doran S et al (2005) Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 48(5):838\u2013848. https:\/\/doi.org\/10.1007\/s00125-005-1732-4","journal-title":"Diabetologia"},{"issue":"4","key":"6833_CR214","doi-asserted-by":"publisher","first-page":"724","DOI":"10.2337\/diacare.25.4.724","volume":"25","author":"F Whitehouse","year":"2002","unstructured":"Whitehouse F, Kruger DF, Fineman M et al (2002) A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 25(4):724\u2013730. https:\/\/doi.org\/10.2337\/diacare.25.4.724","journal-title":"Diabetes Care"},{"issue":"1","key":"6833_CR215","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1089\/15209150252924094","volume":"4","author":"RE Ratner","year":"2002","unstructured":"Ratner RE, Want LL, Fineman MS et al (2002) Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 4(1):51\u201361. https:\/\/doi.org\/10.1089\/15209150252924094","journal-title":"Diabetes Technol Ther"},{"issue":"3","key":"6833_CR216","doi-asserted-by":"publisher","first-page":"784","DOI":"10.2337\/diacare.26.3.784","volume":"26","author":"PA Hollander","year":"2003","unstructured":"Hollander PA, Levy P, Fineman MS et al (2003) Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 26(3):784\u2013790. https:\/\/doi.org\/10.2337\/diacare.26.3.784","journal-title":"Diabetes Care"},{"issue":"11","key":"6833_CR217","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","volume":"21","author":"RE Ratner","year":"2004","unstructured":"Ratner RE, Dickey R, Fineman M et al (2004) Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med 21(11):1204\u20131212. https:\/\/doi.org\/10.1111\/j.1464-5491.2004.01319.x","journal-title":"Diabet Med"},{"issue":"4","key":"6833_CR218","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S2213-8587(21)00019-X","volume":"9","author":"M von Herrath","year":"2021","unstructured":"von Herrath M, Bain SC, Bode B et al (2021) Anti-interleukin-21 antibody and liraglutide for the preservation of beta-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 9(4):212\u2013224. https:\/\/doi.org\/10.1016\/S2213-8587(21)00019-X","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"6833_CR219","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S2213-8587(20)30043-7","volume":"8","author":"MA Nauck","year":"2020","unstructured":"Nauck MA, Meier JJ (2020) GLP-1 receptor agonists in type 1 diabetes: a MAG1C bullet? Lancet Diabetes Endocrinol 8(4):262\u2013264. https:\/\/doi.org\/10.1016\/S2213-8587(20)30043-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"6833_CR220","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.2337\/dc16-0691","volume":"39","author":"C Mathieu","year":"2016","unstructured":"Mathieu C, Zinman B, Hemmingsson JU et al (2016) Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care 39(10):1702\u20131710. https:\/\/doi.org\/10.2337\/dc16-0691","journal-title":"Diabetes Care"},{"issue":"10","key":"6833_CR221","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.2337\/dc16-0690","volume":"39","author":"B Ahren","year":"2016","unstructured":"Ahren B, Hirsch IB, Pieber TR et al (2016) Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial. Diabetes Care 39(10):1693\u20131701. https:\/\/doi.org\/10.2337\/dc16-0690","journal-title":"Diabetes Care"},{"issue":"8","key":"6833_CR222","doi-asserted-by":"publisher","first-page":"EVIDoa2500173","DOI":"10.1056\/EVIDoa2500173","volume":"4","author":"VN Shah","year":"2025","unstructured":"Shah VN, Akturk HK, Kruger D et al (2025) Semaglutide in adults with type 1 diabetes and obesity. NEJM Evid 4(8):EVIDoa2500173. https:\/\/doi.org\/10.1056\/EVIDoa2500173","journal-title":"NEJM Evid"},{"issue":"2","key":"6833_CR223","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1177\/19322968231223991","volume":"19","author":"HK Akturk","year":"2025","unstructured":"Akturk HK, Dong F, Snell-Bergeon JK, Karakus KE, Shah VN (2025) Efficacy and safety of tirzepatide in adults with type 1 diabetes: a proof of concept observational study. J Diabetes Sci Technol 19(2):292\u2013296. https:\/\/doi.org\/10.1177\/19322968231223991","journal-title":"J Diabetes Sci Technol"},{"issue":"1","key":"6833_CR224","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2337\/dc25-2379","volume":"49","author":"JR Snaith","year":"2026","unstructured":"Snaith JR, Frampton R, Samocha-Bonet D, Greenfield JR (2026) Tirzepatide in adults with type 1 diabetes: a phase 2 randomized placebo-controlled clinical trial. Diabetes Care 49(1):161\u2013170. https:\/\/doi.org\/10.2337\/dc25-2379","journal-title":"Diabetes Care"},{"issue":"2","key":"6833_CR225","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.tem.2019.11.007","volume":"31","author":"JR Snaith","year":"2020","unstructured":"Snaith JR, Holmes-Walker DJ, Greenfield JR (2020) Reducing type 1 diabetes mortality: role for adjunctive therapies? Trends Endocrinol Metab 31(2):150\u2013164. https:\/\/doi.org\/10.1016\/j.tem.2019.11.007","journal-title":"Trends Endocrinol Metab"},{"key":"6833_CR226","doi-asserted-by":"publisher","first-page":"1453067","DOI":"10.3389\/fendo.2024.1453067","volume":"15","author":"Y Liu","year":"2024","unstructured":"Liu Y, Yang S, Jiang A, Zou D, Chen Z, Su N (2024) Risk of diabetic ketoacidosis caused by sodium glucose cotransporter-2 inhibitors in patients with type 1 diabetes: a systematic review and network meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne) 15:1453067. https:\/\/doi.org\/10.3389\/fendo.2024.1453067","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"6833_CR227","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S2213-8587(19)30154-8","volume":"7","author":"SI Taylor","year":"2019","unstructured":"Taylor SI, Blau JE, Rother KI, Beitelshees AL (2019) SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks. Lancet Diabetes Endocrinol 7(12):949\u2013958. https:\/\/doi.org\/10.1016\/S2213-8587(19)30154-8","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"6833_CR228","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.2337\/dc18-2316","volume":"42","author":"T Danne","year":"2019","unstructured":"Danne T, Garg S, Peters AL et al (2019) International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care 42(6):1147\u20131154. https:\/\/doi.org\/10.2337\/dc18-2316","journal-title":"Diabetes Care"},{"issue":"2","key":"6833_CR229","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.2337\/dc22-1673","volume":"46","author":"RG McCoy","year":"2023","unstructured":"McCoy RG, Herrin J, Galindo RJ et al (2023) Rates of hypoglycemic and hyperglycemic emergencies among U.S. adults with diabetes, 2011-2020. Diabetes Care 46(2):e69\u2013e71. https:\/\/doi.org\/10.2337\/dc22-1673","journal-title":"Diabetes Care"},{"issue":"6","key":"6833_CR230","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2337\/dc23-1765","volume":"47","author":"JL Sherr","year":"2024","unstructured":"Sherr JL, Laffel LM, Liu J et al (2024) Severe hypoglycemia and impaired awareness of hypoglycemia persist in people with type 1 diabetes despite use of diabetes technology: results from a cross-sectional survey. Diabetes Care 47(6):941\u2013947. https:\/\/doi.org\/10.2337\/dc23-1765","journal-title":"Diabetes Care"},{"issue":"6","key":"6833_CR231","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1111\/jdi.13290","volume":"11","author":"YK Lin","year":"2020","unstructured":"Lin YK, Fisher SJ, Pop-Busui R (2020) Hypoglycemia unawareness and autonomic dysfunction in diabetes: lessons learned and roles of diabetes technologies. J Diabetes Investig 11(6):1388\u20131402. https:\/\/doi.org\/10.1111\/jdi.13290","journal-title":"J Diabetes Investig"},{"issue":"4","key":"6833_CR232","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/j.1464-5491.2008.02413.x","volume":"25","author":"J Geddes","year":"2008","unstructured":"Geddes J, Schopman JE, Zammitt NN, Frier BM (2008) Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes. Diabet Med 25(4):501\u2013504. https:\/\/doi.org\/10.1111\/j.1464-5491.2008.02413.x","journal-title":"Diabet Med"},{"issue":"4","key":"6833_CR233","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1056\/NEJMra1215228","volume":"369","author":"PE Cryer","year":"2013","unstructured":"Cryer PE (2013) Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 369(4):362\u2013372. https:\/\/doi.org\/10.1056\/NEJMra1215228","journal-title":"N Engl J Med"},{"issue":"4","key":"6833_CR234","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2337\/diacare.18.4.517","volume":"18","author":"WL Clarke","year":"1995","unstructured":"Clarke WL, Cox DJ, Gonder-Frederick LA, Julian D, Schlundt D, Polonsky W (1995) Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care 18(4):517\u2013522. https:\/\/doi.org\/10.2337\/diacare.18.4.517","journal-title":"Diabetes Care"},{"issue":"3","key":"6833_CR235","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/dmrr.377","volume":"19","author":"U Pedersen-Bjergaard","year":"2003","unstructured":"Pedersen-Bjergaard U, Pramming S, Thorsteinsson B (2003) Recall of severe hypoglycaemia and self-estimated state of awareness in type 1 diabetes. Diabetes Metab Res Rev 19(3):232\u2013240. https:\/\/doi.org\/10.1002\/dmrr.377","journal-title":"Diabetes Metab Res Rev"},{"issue":"7","key":"6833_CR236","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2337\/diacare.17.7.697","volume":"17","author":"AE Gold","year":"1994","unstructured":"Gold AE, MacLeod KM, Frier BM (1994) Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care 17(7):697\u2013703. https:\/\/doi.org\/10.2337\/diacare.17.7.697","journal-title":"Diabetes Care"},{"issue":"3","key":"6833_CR237","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/dme.12824","volume":"33","author":"J Speight","year":"2016","unstructured":"Speight J, Barendse SM, Singh H et al (2016) Characterizing problematic hypoglycaemia: iterative design and preliminary psychometric validation of the Hypoglycaemia Awareness Questionnaire (HypoA-Q). Diabet Med 33(3):376\u2013385. https:\/\/doi.org\/10.1111\/dme.12824","journal-title":"Diabet Med"},{"issue":"10","key":"6833_CR238","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1007\/s00125-024-06233-1","volume":"67","author":"U Soholm","year":"2024","unstructured":"Soholm U, Broadley M, Zaremba N et al (2024) The impact of hypoglycaemia on daily functioning among adults with diabetes: a prospective observational study using the Hypo-METRICS app. Diabetologia 67(10):2160\u20132174. https:\/\/doi.org\/10.1007\/s00125-024-06233-1","journal-title":"Diabetologia"},{"issue":"5","key":"6833_CR239","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S2213-8587(18)30315-2","volume":"7","author":"International Hypoglycaemia Study Group","year":"2019","unstructured":"International Hypoglycaemia Study Group (2019) Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol 7(5):385\u2013396. https:\/\/doi.org\/10.1016\/S2213-8587(18)30315-2","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"18","key":"6833_CR240","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1056\/NEJMoa066397","volume":"356","author":"Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions Complications Study Research Group","year":"2007","unstructured":"Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions Complications Study Research Group (2007) Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 356(18):1842\u20131852. https:\/\/doi.org\/10.1056\/NEJMoa066397","journal-title":"N Engl J Med"},{"issue":"8","key":"6833_CR241","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.2337\/dc15-0102","volume":"38","author":"E Yeoh","year":"2015","unstructured":"Yeoh E, Choudhary P, Nwokolo M, Ayis S, Amiel SA (2015) Interventions that restore awareness of hypoglycemia in adults with type 1 diabetes: a systematic review and meta-analysis. Diabetes Care 38(8):1592\u20131609. https:\/\/doi.org\/10.2337\/dc15-0102","journal-title":"Diabetes Care"},{"issue":"12","key":"6833_CR242","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.2337\/dc23-0685","volume":"46","author":"E Renard","year":"2023","unstructured":"Renard E, Joubert M, Villard O et al (2023) Safety and efficacy of sustained automated insulin delivery compared with sensor and pump therapy in adults with type 1 diabetes at high risk for hypoglycemia: a randomized controlled trial. Diabetes Care 46(12):2180\u20132187. https:\/\/doi.org\/10.2337\/dc23-0685","journal-title":"Diabetes Care"},{"issue":"5","key":"6833_CR243","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1007\/s00125-025-06366-x","volume":"68","author":"J De Meulemeester","year":"2025","unstructured":"De Meulemeester J, Keymeulen B, De Block C et al (2025) One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study. Diabetologia 68(5):948\u2013960. https:\/\/doi.org\/10.1007\/s00125-025-06366-x","journal-title":"Diabetologia"},{"issue":"2","key":"6833_CR244","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1210\/endrev\/bnac022","volume":"44","author":"M Phillip","year":"2023","unstructured":"Phillip M, Nimri R, Bergenstal RM et al (2023) Consensus recommendations for the use of automated insulin delivery technologies in clinical practice. Endocr Rev 44(2):254\u2013280. https:\/\/doi.org\/10.1210\/endrev\/bnac022","journal-title":"Endocr Rev"},{"issue":"1","key":"6833_CR245","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1089\/dia.2024.0134","volume":"27","author":"KG Tidemand","year":"2025","unstructured":"Tidemand KG, Laugesen C, Ranjan AG, Skovhus LB, Norgaard K (2025) Frequency of rebound hyperglycemia in adults with type 1 diabetes treated with different insulin delivery modalities. Diabetes Technol Ther 27(1):60\u201365. https:\/\/doi.org\/10.1089\/dia.2024.0134","journal-title":"Diabetes Technol Ther"},{"issue":"5","key":"6833_CR246","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/dc19-2449","volume":"43","author":"SR Benoit","year":"2020","unstructured":"Benoit SR, Hora I, Pasquel FJ, Gregg EW, Albright AL, Imperatore G (2020) Trends in emergency department visits and inpatient admissions for hyperglycemic crises in adults with diabetes in the U.S., 2006-2015. Diabetes Care 43(5):1057\u20131064. https:\/\/doi.org\/10.2337\/dc19-2449","journal-title":"Diabetes Care"},{"issue":"11","key":"6833_CR247","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.2337\/dc23-0475","volume":"46","author":"EB Stougaard","year":"2023","unstructured":"Stougaard EB, Amadid H, Sondergaard E et al (2023) Time trends in the incidence of diabetic ketoacidosis leading to hospital admission among adults with type 1 diabetes: a nationwide Danish register study. Diabetes Care 46(11):1897\u20131902. https:\/\/doi.org\/10.2337\/dc23-0475","journal-title":"Diabetes Care"},{"issue":"3","key":"6833_CR248","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.2337\/dc18-1160","volume":"42","author":"H Kalscheuer","year":"2019","unstructured":"Kalscheuer H, Seufert J, Lanzinger S et al (2019) Event rates and risk factors for the development of diabetic ketoacidosis in adult patients with type 1 diabetes: analysis from the DPV registry based on 46,966 patients. Diabetes Care 42(3):e34\u2013e36. https:\/\/doi.org\/10.2337\/dc18-1160","journal-title":"Diabetes Care"},{"issue":"1","key":"6833_CR249","doi-asserted-by":"publisher","first-page":"e000621","DOI":"10.1136\/bmjdrc-2018-000621","volume":"7","author":"E Everett","year":"2019","unstructured":"Everett E, Mathioudakis NN (2019) Association of socioeconomic status and DKA readmission in adults with type 1 diabetes: analysis of the US National Readmission Database. BMJ Open Diabetes Res Care 7(1):e000621. https:\/\/doi.org\/10.1136\/bmjdrc-2018-000621","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"7","key":"6833_CR250","doi-asserted-by":"publisher","first-page":"e14505","DOI":"10.1111\/dme.14505","volume":"38","author":"CJ Garrett","year":"2021","unstructured":"Garrett CJ, Moulton CD, Choudhary P, Amiel SA, Fonagy P, Ismail K (2021) The psychopathology of recurrent diabetic ketoacidosis: a case-control study. Diabet Med 38(7):e14505. https:\/\/doi.org\/10.1111\/dme.14505","journal-title":"Diabet Med"},{"issue":"1","key":"6833_CR251","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/dom.13012","volume":"20","author":"BM Bonora","year":"2018","unstructured":"Bonora BM, Avogaro A, Fadini GP (2018) Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: an updated review of the literature. Diabetes Obes Metab 20(1):25\u201333. https:\/\/doi.org\/10.1111\/dom.13012","journal-title":"Diabetes Obes Metab"},{"key":"6833_CR252","doi-asserted-by":"publisher","unstructured":"Jacobsen LM, Schatz D (2025) Immunotherapy-based strategies for treatment of type 1 diabetes. Horm Res Paediatr\u00a098(4):425\u2013434. https:\/\/doi.org\/10.1159\/000542002","DOI":"10.1159\/000542002"},{"issue":"23","key":"6833_CR253","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa2308743","volume":"389","author":"EL Ramos","year":"2023","unstructured":"Ramos EL, Dayan CM, Chatenoud L et al (2023) Teplizumab and beta-cell function in newly diagnosed type 1 diabetes. N Engl J Med 389(23):2151\u20132161. https:\/\/doi.org\/10.1056\/NEJMoa2308743","journal-title":"N Engl J Med"},{"issue":"6","key":"6833_CR254","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.2337\/db19-0057","volume":"68","author":"MJ Haller","year":"2019","unstructured":"Haller MJ, Long SA, Blanchfield JL et al (2019) Low-dose anti-thymocyte globulin preserves c-peptide, reduces HbA(1c), and increases regulatory to conventional T-cell ratios in new-onset type 1 diabetes: two-year clinical trial data. Diabetes 68(6):1267\u20131276. https:\/\/doi.org\/10.2337\/db19-0057","journal-title":"Diabetes"},{"issue":"21","key":"6833_CR255","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1056\/NEJMoa2006136","volume":"383","author":"T Quattrin","year":"2020","unstructured":"Quattrin T, Haller MJ, Steck AK et al (2020) Golimumab and beta-cell function in youth with new-onset type 1 diabetes. N Engl J Med 383(21):2007\u20132017. https:\/\/doi.org\/10.1056\/NEJMoa2006136","journal-title":"N Engl J Med"},{"issue":"23","key":"6833_CR256","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa2306691","volume":"389","author":"M Waibel","year":"2023","unstructured":"Waibel M, Wentworth JM, So M et al (2023) Baricitinib and beta-cell function in patients with new-onset type 1 diabetes. N Engl J Med 389(23):2140\u20132150. https:\/\/doi.org\/10.1056\/NEJMoa2306691","journal-title":"N Engl J Med"},{"issue":"7","key":"6833_CR257","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1902226","volume":"381","author":"KC Herold","year":"2019","unstructured":"Herold KC, Bundy BN, Long SA et al (2019) An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 381(7):603\u2013613. https:\/\/doi.org\/10.1056\/NEJMoa1902226","journal-title":"N Engl J Med"},{"issue":"10511","key":"6833_CR258","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/S0140-6736(25)01438-2","volume":"406","author":"AG Ziegler","year":"2025","unstructured":"Ziegler AG, Cengiz E, Kay TWH (2025) The future of type 1 diabetes therapy. Lancet 406(10511):1520\u20131534. https:\/\/doi.org\/10.1016\/S0140-6736(25)01438-2","journal-title":"Lancet"},{"issue":"10","key":"6833_CR259","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41574-025-01128-6","volume":"21","author":"FL Henriques","year":"2025","unstructured":"Henriques FL, Buckle I, Forbes JM (2025) Type 1 diabetes mellitus prevention: present and future. Nat Rev Endocrinol 21(10):608\u2013622. https:\/\/doi.org\/10.1038\/s41574-025-01128-6","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"6833_CR260","doi-asserted-by":"publisher","first-page":"e088522","DOI":"10.1136\/bmjopen-2024-088522","volume":"15","author":"L Hoffmann","year":"2025","unstructured":"Hoffmann L, Kohls M, Arnolds S et al (2025) EDENT1FI Master Protocol for screening of presymptomatic early-stage type 1 diabetes in children and adolescents. BMJ Open 15(1):e088522. https:\/\/doi.org\/10.1136\/bmjopen-2024-088522","journal-title":"BMJ Open"},{"issue":"7","key":"6833_CR261","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.2337\/dc19-2003","volume":"43","author":"RB McQueen","year":"2020","unstructured":"McQueen RB, Geno Rasmussen C, Waugh K et al (2020) Cost and cost-effectiveness of large-scale screening for type 1 diabetes in Colorado. Diabetes Care 43(7):1496\u20131503. https:\/\/doi.org\/10.2337\/dc19-2003","journal-title":"Diabetes Care"},{"issue":"4","key":"6833_CR262","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1001\/jama.2019.21565","volume":"323","author":"AG Ziegler","year":"2020","unstructured":"Ziegler AG, Kick K, Bonifacio E et al (2020) Yield of a public health screening of children for islet autoantibodies in Bavaria, Germany. JAMA 323(4):339\u2013351. https:\/\/doi.org\/10.1001\/jama.2019.21565","journal-title":"JAMA"},{"issue":"11","key":"6833_CR263","doi-asserted-by":"publisher","first-page":"e15419","DOI":"10.1111\/dme.15419","volume":"41","author":"KJ Bell","year":"2024","unstructured":"Bell KJ, Brodie S, Couper JJ et al (2024) Protocol for the Australian Type 1 Diabetes National Screening Pilot: assessing the feasibility and acceptability of three general population screening models in children. Diabet Med 41(11):e15419. https:\/\/doi.org\/10.1111\/dme.15419","journal-title":"Diabet Med"},{"issue":"7","key":"6833_CR264","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1016\/j.transproceed.2022.03.059","volume":"54","author":"AC Gruessner","year":"2022","unstructured":"Gruessner AC, Gruessner RWG (2022) The 2022 international pancreas transplant registry report-a review. Transplant Proc 54(7):1918\u20131943. https:\/\/doi.org\/10.1016\/j.transproceed.2022.03.059","journal-title":"Transplant Proc"},{"issue":"5","key":"6833_CR265","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2337\/dc24-1915","volume":"48","author":"MR Rickels","year":"2025","unstructured":"Rickels MR, Ballou CM, Foster NC et al (2025) Islet transplantation versus standard of care for type 1 diabetes complicated by severe hypoglycemia from the collaborative islet transplant registry and the T1D exchange registry. Diabetes Care 48(5):737\u2013744. https:\/\/doi.org\/10.2337\/dc24-1915","journal-title":"Diabetes Care"},{"issue":"6","key":"6833_CR266","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/TP.0000000000000288","volume":"98","author":"N Niclauss","year":"2014","unstructured":"Niclauss N, Morel P, Berney T (2014) Has the gap between pancreas and islet transplantation closed? Transplantation 98(6):593\u2013599. https:\/\/doi.org\/10.1097\/TP.0000000000000288","journal-title":"Transplantation"},{"issue":"6","key":"6833_CR267","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2337\/dc25-0059","volume":"48","author":"Q Perrier","year":"2025","unstructured":"Perrier Q, Jambon-Barbara C, Kessler L et al (2025) Impact of islet transplantation on diabetes complications and mortality in patients living with type 1 diabetes. Diabetes Care 48(6):1007\u20131015. https:\/\/doi.org\/10.2337\/dc25-0059","journal-title":"Diabetes Care"},{"issue":"4","key":"6833_CR268","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1097\/SLA.0000000000006415","volume":"280","author":"EB Finger","year":"2024","unstructured":"Finger EB, Matar AJ, Dunn TB et al (2024) Evolution of pancreas transplantation at a single institution-50+ years and 2500 transplants. Ann Surg 280(4):604\u2013615. https:\/\/doi.org\/10.1097\/SLA.0000000000006415","journal-title":"Ann Surg"},{"issue":"4","key":"6833_CR269","doi-asserted-by":"publisher","first-page":"R73","DOI":"10.1093\/ejendo\/lvad032","volume":"188","author":"AO Al-Naseem","year":"2023","unstructured":"Al-Naseem AO, Attia A, Gonnah AR et al (2023) Pancreas transplantation today: quo vadis? Eur J Endocrinol 188(4):R73\u2013R87. https:\/\/doi.org\/10.1093\/ejendo\/lvad032","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"6833_CR270","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1097\/TXD.0000000000000581","volume":"2","author":"J Speight","year":"2016","unstructured":"Speight J, Woodcock AJ, Reaney MD et al (2016) Well, I wouldn\u2019t be any worse off, would I, than I am now? A qualitative study of decision-making, hopes, and realities of adults with type 1 diabetes undergoing islet cell transplantation. Transplant Direct 2(5):e72. https:\/\/doi.org\/10.1097\/TXD.0000000000000581","journal-title":"Transplant Direct"},{"issue":"2","key":"6833_CR271","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40259-025-00703-7","volume":"39","author":"A Rech Tondin","year":"2025","unstructured":"Rech Tondin A, Lanzoni G (2025) Islet cell replacement and regeneration for type 1 diabetes: current developments and future prospects. BioDrugs 39(2):261\u2013280. https:\/\/doi.org\/10.1007\/s40259-025-00703-7","journal-title":"BioDrugs"},{"key":"6833_CR272","doi-asserted-by":"publisher","unstructured":"Lemos JRN, Skyler JS (2024) Challenges in beta cell replacement for type 1 diabetes. Horm Res Paediatr 1\u201315. https:\/\/doi.org\/10.1159\/000542206","DOI":"10.1159\/000542206"},{"issue":"7","key":"6833_CR273","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1097\/TP.0000000000005334","volume":"109","author":"H Choksi","year":"2025","unstructured":"Choksi H, Pleass H, Robertson P, Au E, Rogers N (2025) Long-term metabolic outcomes post-simultaneous pancreas-kidney transplantation in recipients with type 1 diabetes. Transplantation 109(7):1222\u20131229. https:\/\/doi.org\/10.1097\/TP.0000000000005334","journal-title":"Transplantation"},{"issue":"4","key":"6833_CR274","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1097\/SLA.0b013e3181b76d2b","volume":"250","author":"HW Sollinger","year":"2009","unstructured":"Sollinger HW, Odorico JS, Becker YT, D\u2019Alessandro AM, Pirsch JD (2009) One thousand simultaneous pancreas-kidney transplants at a single center with 22-year follow-up. Ann Surg 250(4):618\u2013630. https:\/\/doi.org\/10.1097\/SLA.0b013e3181b76d2b","journal-title":"Ann Surg"},{"issue":"2","key":"6833_CR275","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.transproceed.2006.01.005","volume":"38","author":"R Kandaswamy","year":"2006","unstructured":"Kandaswamy R, Sutherland DE (2006) Pancreas versus islet transplantation in diabetes mellitus: how to allocate deceased donor pancreata? Transplant Proc 38(2):365\u2013367. https:\/\/doi.org\/10.1016\/j.transproceed.2006.01.005","journal-title":"Transplant Proc"},{"issue":"4","key":"6833_CR276","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2337\/diacare.29.04.06.dc06-9908","volume":"29","author":"RP Robertson","year":"2006","unstructured":"Robertson RP, Davis C, Larsen J, Stratta R, Sutherland DE, American Diabetes Association (2006) Pancreas and islet transplantation in type 1 diabetes. Diabetes Care 29(4):935. https:\/\/doi.org\/10.2337\/diacare.29.04.06.dc06-9908","journal-title":"Diabetes Care"},{"issue":"6","key":"6833_CR277","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.2337\/dc15-0090","volume":"38","author":"P Choudhary","year":"2015","unstructured":"Choudhary P, Rickels MR, Senior PA et al (2015) Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia. Diabetes Care 38(6):1016\u20131029. https:\/\/doi.org\/10.2337\/dc15-0090","journal-title":"Diabetes Care"},{"issue":"4","key":"6833_CR278","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1089\/dia.2014.0289","volume":"17","author":"PA Senior","year":"2015","unstructured":"Senior PA, Bellin MD, Alejandro R et al (2015) Consistency of quantitative scores of hypoglycemia severity and glycemic lability and comparison with continuous glucose monitoring system measures in long-standing type 1 diabetes. Diabetes Technol Ther 17(4):235\u2013242. https:\/\/doi.org\/10.1089\/dia.2014.0289","journal-title":"Diabetes Technol Ther"},{"issue":"4","key":"6833_CR279","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2337\/diabetes.53.4.955","volume":"53","author":"EA Ryan","year":"2004","unstructured":"Ryan EA, Shandro T, Green K et al (2004) Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 53(4):955\u2013962. https:\/\/doi.org\/10.2337\/diabetes.53.4.955","journal-title":"Diabetes"},{"issue":"7","key":"6833_CR280","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.2337\/dc12-0063","volume":"35","author":"FB Barton","year":"2012","unstructured":"Barton FB, Rickels MR, Alejandro R et al (2012) Improvement in outcomes of clinical islet transplantation: 1999\u20132010. Diabetes Care 35(7):1436\u20131445. https:\/\/doi.org\/10.2337\/dc12-0063","journal-title":"Diabetes Care"},{"issue":"7","key":"6833_CR281","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S2213-8587(22)00114-0","volume":"10","author":"BA Marfil-Garza","year":"2022","unstructured":"Marfil-Garza BA, Imes S, Verhoeff K et al (2022) Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada. Lancet Diabetes Endocrinol 10(7):519\u2013532. https:\/\/doi.org\/10.1016\/S2213-8587(22)00114-0","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"6833_CR282","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S2213-8587(24)00341-3","volume":"13","author":"D Catarinella","year":"2025","unstructured":"Catarinella D, Melzi R, Mercalli A et al (2025) Long-term outcomes of pancreatic islet transplantation alone in type 1 diabetes: a 20-year single-centre study in Italy. Lancet Diabetes Endocrinol 13(4):279\u2013293. https:\/\/doi.org\/10.1016\/S2213-8587(24)00341-3","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"6833_CR283","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1111\/ajt.12250","volume":"13","author":"PJ O'Connell","year":"2013","unstructured":"O\u2019Connell PJ, Holmes-Walker DJ, Goodman D et al (2013) Multicenter Australian trial of islet transplantation: improving accessibility and outcomes. Am J Transplant 13(7):1850\u20131858. https:\/\/doi.org\/10.1111\/ajt.12250","journal-title":"Am J Transplant"},{"issue":"7","key":"6833_CR284","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S2213-8587(18)30078-0","volume":"6","author":"S Lablanche","year":"2018","unstructured":"Lablanche S, Vantyghem MC, Kessler L et al (2018) Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol 6(7):527\u2013537. https:\/\/doi.org\/10.1016\/S2213-8587(18)30078-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6833_CR285","doi-asserted-by":"publisher","first-page":"11659","DOI":"10.3389\/ti.2023.11659","volume":"36","author":"Z Bond","year":"2023","unstructured":"Bond Z, Malik S, Bashir A et al (2023) Validation of Igls criteria for islet transplant functional status using person-reported outcome measures in a cross-sectional study. Transpl Int 36:11659. https:\/\/doi.org\/10.3389\/ti.2023.11659","journal-title":"Transpl Int"},{"key":"6833_CR286","doi-asserted-by":"publisher","first-page":"1391504","DOI":"10.3389\/fimmu.2024.1391504","volume":"15","author":"Q Wang","year":"2024","unstructured":"Wang Q, Huang YX, Liu L et al (2024) Pancreatic islet transplantation: current advances and challenges. Front Immunol 15:1391504. https:\/\/doi.org\/10.3389\/fimmu.2024.1391504","journal-title":"Front Immunol"},{"issue":"9","key":"6833_CR287","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1056\/NEJMoa2506549","volume":"393","author":"TW Reichman","year":"2025","unstructured":"Reichman TW, Markmann JF, Odorico J et al (2025) Stem cell-derived, fully differentiated islets for type 1 diabetes. N Engl J Med 393(9):858\u2013868. https:\/\/doi.org\/10.1056\/NEJMoa2506549","journal-title":"N Engl J Med"},{"issue":"9","key":"6833_CR288","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41574-020-0375-3","volume":"16","author":"GG Nair","year":"2020","unstructured":"Nair GG, Tzanakakis ES, Hebrok M (2020) Emerging routes to the generation of functional beta-cells for diabetes mellitus cell therapy. Nat Rev Endocrinol 16(9):506\u2013518. https:\/\/doi.org\/10.1038\/s41574-020-0375-3","journal-title":"Nat Rev Endocrinol"},{"issue":"20","key":"6833_CR289","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa2120238","volume":"386","author":"RA Montgomery","year":"2022","unstructured":"Montgomery RA, Stern JM, Lonze BE et al (2022) Results of two cases of pig-to-human kidney xenotransplantation. N Engl J Med 386(20):1889\u20131898. https:\/\/doi.org\/10.1056\/NEJMoa2120238","journal-title":"N Engl J Med"},{"issue":"22","key":"6833_CR290","doi-asserted-by":"publisher","first-page":"6152","DOI":"10.1016\/j.cell.2024.09.004","volume":"187","author":"S Wang","year":"2024","unstructured":"Wang S, Du Y, Zhang B et al (2024) Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient. Cell 187(22):6152-6164 e6118. https:\/\/doi.org\/10.1016\/j.cell.2024.09.004","journal-title":"Cell"},{"issue":"5","key":"6833_CR291","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.stem.2023.04.002","volume":"30","author":"NJ Hogrebe","year":"2023","unstructured":"Hogrebe NJ, Ishahak M, Millman JR (2023) Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes. Cell Stem Cell 30(5):530\u2013548. https:\/\/doi.org\/10.1016\/j.stem.2023.04.002","journal-title":"Cell Stem Cell"},{"key":"6833_CR292","doi-asserted-by":"publisher","first-page":"115205","DOI":"10.1016\/j.addr.2024.115205","volume":"207","author":"S Kioulaphides","year":"2024","unstructured":"Kioulaphides S, Garcia AJ (2024) Encapsulation and immune protection for type 1 diabetes cell therapy. Adv Drug Deliv Rev 207:115205. https:\/\/doi.org\/10.1016\/j.addr.2024.115205","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"6833_CR293","doi-asserted-by":"publisher","first-page":"100879","DOI":"10.1016\/j.xcrm.2022.100879","volume":"4","author":"D Gerace","year":"2023","unstructured":"Gerace D, Zhou Q, Kenty JH et al (2023) Engineering human stem cell-derived islets to evade immune rejection and promote localized immune tolerance. Cell Rep Med 4(1):100879. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100879","journal-title":"Cell Rep Med"},{"issue":"10","key":"6833_CR294","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-8587(21)00170-4","volume":"9","author":"NAJ Krentz","year":"2021","unstructured":"Krentz NAJ, Shea LD, Huising MO, Shaw JAM (2021) Restoring normal islet mass and function in type 1 diabetes through regenerative medicine and tissue engineering. Lancet Diabetes Endocrinol 9(10):708\u2013724. https:\/\/doi.org\/10.1016\/S2213-8587(21)00170-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6833_CR295","doi-asserted-by":"publisher","first-page":"1612576","DOI":"10.3389\/fendo.2025.1612576","volume":"16","author":"RC Vasavada","year":"2025","unstructured":"Vasavada RC, Dhawan S (2025) Harnessing beta-cell replication: advancing molecular insights to regenerative therapies in diabetes. Front Endocrinol (Lausanne) 16:1612576. https:\/\/doi.org\/10.3389\/fendo.2025.1612576","journal-title":"Front Endocrinol (Lausanne)"},{"key":"6833_CR296","doi-asserted-by":"publisher","first-page":"101477","DOI":"10.1016\/j.molmet.2022.101477","volume":"60","author":"G Basile","year":"2022","unstructured":"Basile G, Qadir MMF, Mauvais-Jarvis F et al (2022) Emerging diabetes therapies: bringing back the beta-cells. Mol Metab 60:101477. https:\/\/doi.org\/10.1016\/j.molmet.2022.101477","journal-title":"Mol Metab"},{"key":"6833_CR297","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.diabres.2016.09.024","volume":"122","author":"RS Weinstock","year":"2016","unstructured":"Weinstock RS, Schutz-Fuhrmann I, Connor CG et al (2016) Type 1 diabetes in older adults: comparing treatments and chronic complications in the United States T1D Exchange and the German\/Austrian DPV registries. Diabetes Res Clin Pract 122:28\u201337. https:\/\/doi.org\/10.1016\/j.diabres.2016.09.024","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"6833_CR298","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1001\/archopht.122.4.546","volume":"122","author":"MS Roy","year":"2004","unstructured":"Roy MS, Klein R, O\u2019Colmain BJ, Klein BE, Moss SE, Kempen JH (2004) The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the United States. Arch Ophthalmol 122(4):546\u2013551. https:\/\/doi.org\/10.1001\/archopht.122.4.546","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"6833_CR299","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.ophtha.2016.01.043","volume":"123","author":"PS Silva","year":"2016","unstructured":"Silva PS, Horton MB, Clary D et al (2016) Identification of diabetic retinopathy and ungradable image rate with ultrawide field imaging in a national teleophthalmology program. Ophthalmology 123(6):1360\u20131367. https:\/\/doi.org\/10.1016\/j.ophtha.2016.01.043","journal-title":"Ophthalmology"},{"issue":"2","key":"6833_CR300","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1001\/jamaophthalmol.2015.5083","volume":"134","author":"OB Walton","year":"2016","unstructured":"Walton OB, Garoon RB, Weng CY et al (2016) Evaluation of automated teleretinal screening program for diabetic retinopathy. JAMA Ophthalmol 134(2):204\u2013209. https:\/\/doi.org\/10.1001\/jamaophthalmol.2015.5083","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"6833_CR301","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1007\/s00125-011-2257-7","volume":"54","author":"T Aspelund","year":"2011","unstructured":"Aspelund T, Thornorisdottir O, Olafsdottir E et al (2011) Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy. Diabetologia 54(10):2525\u20132532. https:\/\/doi.org\/10.1007\/s00125-011-2257-7","journal-title":"Diabetologia"},{"issue":"11","key":"6833_CR302","doi-asserted-by":"publisher","first-page":"109178","DOI":"10.1016\/j.jdiacomp.2025.109178","volume":"39","author":"KY Chen","year":"2025","unstructured":"Chen KY, Chan HC, Chan CM (2025) Can fibrate therapy redefine the management of diabetic retinopathy? A comprehensive systematic review and meta-analysis of efficacy and safety. J Diabetes Complications 39(11):109178. https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109178","journal-title":"J Diabetes Complications"},{"issue":"8","key":"6833_CR303","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/S2213-8587(23)00168-7","volume":"11","author":"HJ Heerspink","year":"2023","unstructured":"Heerspink HJ, Cherney DZ, Groop PH et al (2023) People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action. Lancet Diabetes Endocrinol 11(8):536\u2013540. https:\/\/doi.org\/10.1016\/S2213-8587(23)00168-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"6833_CR304","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2337\/dc17-2364","volume":"41","author":"J Helve","year":"2018","unstructured":"Helve J, Sund R, Arffman M et al (2018) Incidence of end-stage renal disease in patients with type 1 diabetes. Diabetes Care 41(3):434\u2013439. https:\/\/doi.org\/10.2337\/dc17-2364","journal-title":"Diabetes Care"},{"key":"6833_CR305","doi-asserted-by":"publisher","first-page":"101130","DOI":"10.1016\/j.lana.2025.101130","volume":"47","author":"KR Tuttle","year":"2025","unstructured":"Tuttle KR, Reynolds CL, Kornowske LM et al (2025) Prevalence and severity of chronic kidney disease in a population with type 1 diabetes from a United States health system: a real-world cohort study. Lancet Reg Health Am 47:101130. https:\/\/doi.org\/10.1016\/j.lana.2025.101130","journal-title":"Lancet Reg Health Am"},{"key":"6833_CR306","doi-asserted-by":"publisher","first-page":"1282818","DOI":"10.3389\/fneph.2023.1282818","volume":"3","author":"F Jansson Sigfrids","year":"2023","unstructured":"Jansson Sigfrids F, Groop PH (2023) Progression and regression of kidney disease in type 1 diabetes. Front Nephrol 3:1282818. https:\/\/doi.org\/10.3389\/fneph.2023.1282818","journal-title":"Front Nephrol"},{"issue":"1","key":"6833_CR307","first-page":"49","volume":"5","author":"O Gheith","year":"2016","unstructured":"Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T (2016) Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol 5(1):49\u201356","journal-title":"J Nephropharmacol"},{"issue":"12","key":"6833_CR308","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T et al (2022) Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 45(12):3075\u20133090. https:\/\/doi.org\/10.2337\/dci22-0027","journal-title":"Diabetes Care"},{"issue":"10","key":"6833_CR309","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa2512854","volume":"394","author":"HJL Heerspink","year":"2026","unstructured":"Heerspink HJL, Birkenfeld AL, Cherney DZI et al (2026) Finerenone in type 1 diabetes and chronic kidney disease. N Engl J Med 394(10):947\u2013957. https:\/\/doi.org\/10.1056\/NEJMoa2512854","journal-title":"N Engl J Med"},{"issue":"4S","key":"6833_CR310","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes CKD Work Group (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105(4S):S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"issue":"4","key":"6833_CR311","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1111\/dom.16200","volume":"27","author":"A Akerkar","year":"2025","unstructured":"Akerkar A, Ronn PF, Kosjerina V et al (2025) Cumulative risk of diabetic foot complications in risk groups of type 1 and type 2 diabetes: real-world evidence from a 22-year follow-up study. Diabetes Obes Metab 27(4):2284\u20132287. https:\/\/doi.org\/10.1111\/dom.16200","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"6833_CR312","doi-asserted-by":"publisher","first-page":"e3657","DOI":"10.1002\/dmrr.3657","volume":"40","author":"NC Schaper","year":"2024","unstructured":"Schaper NC, van Netten JJ, Apelqvist J et al (2024) Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update). Diabetes Metab Res Rev 40(3):e3657. https:\/\/doi.org\/10.1002\/dmrr.3657","journal-title":"Diabetes Metab Res Rev"},{"issue":"6","key":"6833_CR313","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11892-009-0069-7","volume":"9","author":"R Freeman","year":"2009","unstructured":"Freeman R (2009) Not all neuropathy in diabetes is of diabetic etiology: differential diagnosis of diabetic neuropathy. Curr Diab Rep 9(6):423\u2013431. https:\/\/doi.org\/10.1007\/s11892-009-0069-7","journal-title":"Curr Diab Rep"},{"issue":"1","key":"6833_CR314","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4239\/wjd.v9.i1.1","volume":"9","author":"VA Serhiyenko","year":"2018","unstructured":"Serhiyenko VA, Serhiyenko AA (2018) Cardiac autonomic neuropathy: risk factors, diagnosis and treatment. World J Diabetes 9(1):1\u201324. https:\/\/doi.org\/10.4239\/wjd.v9.i1.1","journal-title":"World J Diabetes"},{"issue":"4","key":"6833_CR315","doi-asserted-by":"publisher","first-page":"251","DOI":"10.14797\/mdcj-14-4-251","volume":"14","author":"S Agashe","year":"2018","unstructured":"Agashe S, Petak S (2018) Cardiac autonomic neuropathy in diabetes mellitus. Methodist Debakey Cardiovasc J 14(4):251\u2013256. https:\/\/doi.org\/10.14797\/mdcj-14-4-251","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"13","key":"6833_CR316","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMra2311526","volume":"390","author":"C Manrique-Acevedo","year":"2024","unstructured":"Manrique-Acevedo C, Hirsch IB, Eckel RH (2024) Prevention of cardiovascular disease in type 1 diabetes. N Engl J Med 390(13):1207\u20131217. https:\/\/doi.org\/10.1056\/NEJMra2311526","journal-title":"N Engl J Med"},{"issue":"25","key":"6833_CR317","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1056\/NEJMoa052187","volume":"353","author":"DM Nathan","year":"2005","unstructured":"Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353(25):2643\u20132653. https:\/\/doi.org\/10.1056\/NEJMoa052187","journal-title":"N Engl J Med"},{"issue":"20","key":"6833_CR318","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1901281","volume":"384","author":"CE Lewis","year":"2021","unstructured":"Sprint Research Group, Lewis CE, Fine LJ et al (2021) Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med 384(20):1921\u20131930. https:\/\/doi.org\/10.1056\/NEJMoa1901281","journal-title":"N Engl J Med"},{"issue":"12","key":"6833_CR319","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/NEJMoa2412006","volume":"392","author":"Y Bi","year":"2025","unstructured":"Bi Y, Li M, Liu Y et al (2025) Intensive blood-pressure control in patients with type 2 diabetes. N Engl J Med 392(12):1155\u20131167. https:\/\/doi.org\/10.1056\/NEJMoa2412006","journal-title":"N Engl J Med"},{"issue":"6","key":"6833_CR320","doi-asserted-by":"publisher","first-page":"996","DOI":"10.2337\/dc15-2450","volume":"39","author":"C Hero","year":"2016","unstructured":"Hero C, Rawshani A, Svensson AM et al (2016) Association between use of lipid-lowering therapy and cardiovascular diseases and death in individuals with type 1 diabetes. Diabetes Care 39(6):996\u20131003. https:\/\/doi.org\/10.2337\/dc15-2450","journal-title":"Diabetes Care"},{"issue":"11","key":"6833_CR321","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1161\/CIRCULATIONAHA.115.018844","volume":"133","author":"D Vistisen","year":"2016","unstructured":"Vistisen D, Andersen GS, Hansen CS et al (2016) Prediction of first cardiovascular disease event in type 1 diabetes mellitus: the steno type 1 risk engine. Circulation 133(11):1058\u20131066. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018844","journal-title":"Circulation"},{"key":"6833_CR322","doi-asserted-by":"publisher","first-page":"j2099","DOI":"10.1136\/bmj.j2099","volume":"357","author":"J Hippisley-Cox","year":"2017","unstructured":"Hippisley-Cox J, Coupland C, Brindle P (2017) Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 357:j2099. https:\/\/doi.org\/10.1136\/bmj.j2099","journal-title":"BMJ"},{"issue":"13","key":"6833_CR323","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.jacc.2015.01.036","volume":"65","author":"R Puri","year":"2015","unstructured":"Puri R, Nicholls SJ, Shao M et al (2015) Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol 65(13):1273\u20131282. https:\/\/doi.org\/10.1016\/j.jacc.2015.01.036","journal-title":"J Am Coll Cardiol"},{"key":"6833_CR324","doi-asserted-by":"publisher","first-page":"110805","DOI":"10.1016\/j.diabres.2023.110805","volume":"202","author":"M Haji","year":"2023","unstructured":"Haji M, Erqou S, Fonarow GC, Echouffo-Tcheugui JB (2023) Type 1 diabetes and risk of heart failure: a systematic review and meta-analysis. Diabetes Res Clin Pract 202:110805. https:\/\/doi.org\/10.1016\/j.diabres.2023.110805","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"6833_CR325","doi-asserted-by":"publisher","first-page":"427","DOI":"10.7326\/M22-3078","volume":"176","author":"M Fang","year":"2023","unstructured":"Fang M, Jeon Y, Echouffo-Tcheugui JB, Selvin E (2023) Prevalence and management of obesity in U.S. adults with type 1 diabetes. Ann Intern Med 176(3):427\u2013429. https:\/\/doi.org\/10.7326\/M22-3078","journal-title":"Ann Intern Med"},{"key":"6833_CR326","doi-asserted-by":"publisher","first-page":"108973","DOI":"10.1016\/j.diabres.2021.108973","volume":"178","author":"A Welters","year":"2021","unstructured":"Welters A, Tittel SR, Laubner K et al (2021) Long-term trends of BMI and cardiometabolic risk factors among adults with type 1 diabetes: an observational study from the German\/Austrian DPV registry. Diabetes Res Clin Pract 178:108973. https:\/\/doi.org\/10.1016\/j.diabres.2021.108973","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"6833_CR327","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(21)00246-1","volume":"9","author":"B Van der Schueren","year":"2021","unstructured":"Van der Schueren B, Ellis D, Faradji RN, Al-Ozairi E, Rosen J, Mathieu C (2021) Obesity in people living with type 1 diabetes. Lancet Diabetes Endocrinol 9(11):776\u2013785. https:\/\/doi.org\/10.1016\/S2213-8587(21)00246-1","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"6833_CR328","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/dom.14911","volume":"25","author":"D Igudesman","year":"2023","unstructured":"Igudesman D, Crandell J, Corbin KD et al (2023) Weight management in young adults with type 1 diabetes: the advancing care for type 1 diabetes and obesity network sequential multiple assignment randomized trial pilot results. Diabetes Obes Metab 25(3):688\u2013699. https:\/\/doi.org\/10.1111\/dom.14911","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"6833_CR329","doi-asserted-by":"publisher","first-page":"e0194987","DOI":"10.1371\/journal.pone.0194987","volume":"13","author":"JL Turton","year":"2018","unstructured":"Turton JL, Raab R, Rooney KB (2018) Low-carbohydrate diets for type 1 diabetes mellitus: a systematic review. PLoS One 13(3):e0194987. https:\/\/doi.org\/10.1371\/journal.pone.0194987","journal-title":"PLoS One"},{"issue":"1","key":"6833_CR330","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2337\/dc16-1472","volume":"40","author":"A Ranjan","year":"2017","unstructured":"Ranjan A, Schmidt S, Damm-Frydenberg C et al (2017) Low-carbohydrate diet impairs the effect of glucagon in the treatment of insulin-induced mild hypoglycemia: a randomized crossover study. Diabetes Care 40(1):132\u2013135. https:\/\/doi.org\/10.2337\/dc16-1472","journal-title":"Diabetes Care"},{"issue":"2","key":"6833_CR331","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3390\/jcm8020253","volume":"8","author":"N Wu","year":"2019","unstructured":"Wu N, Bredin SSD, Guan Y et al (2019) Cardiovascular health benefits of exercise training in persons living with type 1 diabetes: a systematic review and meta-analysis. J Clin Med 8(2):253. https:\/\/doi.org\/10.3390\/jcm8020253","journal-title":"J Clin Med"},{"issue":"7","key":"6833_CR332","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/jama.2024.10816","volume":"332","author":"KA Gudzune","year":"2024","unstructured":"Gudzune KA, Kushner RF (2024) Medications for obesity: a review. JAMA 332(7):571\u2013584. https:\/\/doi.org\/10.1001\/jama.2024.10816","journal-title":"JAMA"},{"issue":"3","key":"6833_CR333","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1089\/dia.2023.0490","volume":"26","author":"SK Garg","year":"2024","unstructured":"Garg SK, Kaur G, Haider Z, Rodriquez E, Beatson C, Snell-Bergeon J (2024) Efficacy of semaglutide in overweight and obese patients with type 1 diabetes. Diabetes Technol Ther 26(3):184\u2013189. https:\/\/doi.org\/10.1089\/dia.2023.0490","journal-title":"Diabetes Technol Ther"},{"issue":"7","key":"6833_CR334","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s13300-024-01592-9","volume":"15","author":"KE Karakus","year":"2024","unstructured":"Karakus KE, Klein MP, Akturk HK, Shah VN (2024) Changes in basal and bolus insulin requirements with tirzepatide as an adjunctive therapy in adults with type 1 diabetes using tandem control-IQ. Diabetes Ther 15(7):1647\u20131655. https:\/\/doi.org\/10.1007\/s13300-024-01592-9","journal-title":"Diabetes Ther"},{"issue":"3","key":"6833_CR335","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.2337\/dc13-1736","volume":"37","author":"SA Brethauer","year":"2014","unstructured":"Brethauer SA, Aminian A, Rosenthal RJ, Kirwan JP, Kashyap SR, Schauer PR (2014) Bariatric surgery improves the metabolic profile of morbidly obese patients with type 1 diabetes. Diabetes Care 37(3):e51-52. https:\/\/doi.org\/10.2337\/dc13-1736","journal-title":"Diabetes Care"},{"issue":"5","key":"6833_CR336","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s11695-022-05980-7","volume":"32","author":"M Kermansaravi","year":"2022","unstructured":"Kermansaravi M, Valizadeh R, Jazi AD et al (2022) Current status of metabolic\/bariatric surgery in type 1 diabetes mellitus: an updated systematic review and meta-analysis. Obes Surg 32(5):1726\u20131733. https:\/\/doi.org\/10.1007\/s11695-022-05980-7","journal-title":"Obes Surg"},{"issue":"8","key":"6833_CR337","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.2337\/dc14-0583","volume":"37","author":"M Lannoo","year":"2014","unstructured":"Lannoo M, Dillemans B, Van Nieuwenhove Y et al (2014) Bariatric surgery induces weight loss but does not improve glycemic control in patients with type 1 diabetes. Diabetes Care 37(8):e173-174. https:\/\/doi.org\/10.2337\/dc14-0583","journal-title":"Diabetes Care"},{"issue":"6","key":"6833_CR338","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s13300-025-01709-8","volume":"16","author":"C Carette","year":"2025","unstructured":"Carette C, Rives-Lange C, Shoung N et al (2025) Lights and shadows of bariatric surgery: insights from a nationwide administrative database of people living with type 1 diabetes and obesity. Diabetes Ther 16(6):1267\u20131277. https:\/\/doi.org\/10.1007\/s13300-025-01709-8","journal-title":"Diabetes Ther"},{"issue":"2","key":"6833_CR339","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41574-024-01046-z","volume":"21","author":"D Tomic","year":"2025","unstructured":"Tomic D, Harding JL, Jenkins AJ, Shaw JE, Magliano DJ (2025) The epidemiology of type 1 diabetes mellitus in older adults. Nat Rev Endocrinol 21(2):92\u2013104. https:\/\/doi.org\/10.1038\/s41574-024-01046-z","journal-title":"Nat Rev Endocrinol"},{"key":"6833_CR340","doi-asserted-by":"publisher","first-page":"e078432","DOI":"10.1136\/bmj-2023-078432","volume":"385","author":"K Yang","year":"2024","unstructured":"Yang K, Yang X, Jin C et al (2024) Global burden of type 1 diabetes in adults aged 65 years and older, 1990\u20132019: population based study. BMJ 385:e078432. https:\/\/doi.org\/10.1136\/bmj-2023-078432","journal-title":"BMJ"},{"issue":"6","key":"6833_CR341","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1089\/dia.2021.0503","volume":"24","author":"KM Miller","year":"2022","unstructured":"Miller KM, Kanapka LG, Rickels MR et al (2022) Benefit of continuous glucose monitoring in reducing hypoglycemia is sustained through 12 months of use among older adults with type 1 diabetes. Diabetes Technol Ther 24(6):424\u2013434. https:\/\/doi.org\/10.1089\/dia.2021.0503","journal-title":"Diabetes Technol Ther"},{"issue":"5","key":"6833_CR342","doi-asserted-by":"publisher","first-page":"694","DOI":"10.2337\/dc24-1069","volume":"48","author":"MN Munshi","year":"2025","unstructured":"Munshi MN, Slyne C, Adam A et al (2025) Continuous glucose monitoring with geriatric principles in older adults with type 1 diabetes and hypoglycemia: a randomized controlled trial. Diabetes Care 48(5):694\u2013702. https:\/\/doi.org\/10.2337\/dc24-1069","journal-title":"Diabetes Care"},{"key":"6833_CR343","doi-asserted-by":"publisher","unstructured":"Weinstock RS, Raghinaru D, Gal RL et al (2024) Older adults benefit from virtual support for continuous glucose monitor use but require longer visits. J Diabetes Sci Technol 19322968241294250. https:\/\/doi.org\/10.1177\/19322968241294250","DOI":"10.1177\/19322968241294250"},{"issue":"19\u201320","key":"6833_CR344","doi-asserted-by":"publisher","first-page":"7483","DOI":"10.1111\/jocn.16808","volume":"32","author":"NA Allen","year":"2023","unstructured":"Allen NA, Grigorian EG, Mansfield K, Berg CA, Litchman ML (2023) Continuous glucose monitoring with data sharing in older adults: a qualitative study. J Clin Nurs 32(19\u201320):7483\u20137494. https:\/\/doi.org\/10.1111\/jocn.16808","journal-title":"J Clin Nurs"},{"issue":"1","key":"6833_CR345","doi-asserted-by":"publisher","first-page":"EVIDoa2400200","DOI":"10.1056\/EVIDoa2400200","volume":"4","author":"YC Kudva","year":"2025","unstructured":"Kudva YC, Henderson RJ, Kanapka LG et al (2025) Automated insulin delivery in older adults with type 1 diabetes. NEJM Evid 4(1):EVIDoa2400200. https:\/\/doi.org\/10.1056\/EVIDoa2400200","journal-title":"NEJM Evid"},{"issue":"7","key":"6833_CR346","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1089\/dia.2024.0560","volume":"27","author":"YC Kudva","year":"2025","unstructured":"Kudva YC, Henderson RJ, Kanapka LG et al (2025) Automated insulin delivery in elderly with type 1 diabetes: a prespecified analysis of the extension phase. Diabetes Technol Ther 27(7):572\u2013575. https:\/\/doi.org\/10.1089\/dia.2024.0560","journal-title":"Diabetes Technol Ther"},{"issue":"2","key":"6833_CR347","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2337\/dc21-1667","volume":"45","author":"SA McAuley","year":"2022","unstructured":"McAuley SA, Trawley S, Vogrin S et al (2022) Closed-loop insulin delivery versus sensor-augmented pump therapy in older adults with type 1 diabetes (ORACL): a randomized, crossover trial. Diabetes Care 45(2):381\u2013390. https:\/\/doi.org\/10.2337\/dc21-1667","journal-title":"Diabetes Care"},{"issue":"3","key":"6833_CR348","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1016\/S2666-7568(22)00005-8","volume":"3","author":"CK Boughton","year":"2022","unstructured":"Boughton CK, Hartnell S, Thabit H et al (2022) Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study. Lancet Healthy Longev 3(3):e135\u2013e142. https:\/\/doi.org\/10.1016\/S2666-7568(22)00005-8","journal-title":"Lancet Healthy Longev"},{"issue":"6","key":"6833_CR349","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.2337\/dc08-2061","volume":"32","author":"DM Jensen","year":"2009","unstructured":"Jensen DM, Korsholm L, Ovesen P et al (2009) Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. Diabetes Care 32(6):1046\u20131048. https:\/\/doi.org\/10.2337\/dc08-2061","journal-title":"Diabetes Care"},{"issue":"4","key":"6833_CR350","doi-asserted-by":"publisher","first-page":"162","DOI":"10.5694\/mja16.00443","volume":"205","author":"SK Abell","year":"2016","unstructured":"Abell SK, Boyle JA, de Courten B et al (2016) Contemporary type 1 diabetes pregnancy outcomes: impact of obesity and glycaemic control. Med J Aust 205(4):162\u2013167. https:\/\/doi.org\/10.5694\/mja16.00443","journal-title":"Med J Aust"},{"issue":"10110","key":"6833_CR351","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1016\/S0140-6736(17)32400-5","volume":"390","author":"DS Feig","year":"2017","unstructured":"Feig DS, Donovan LE, Corcoy R et al (2017) Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet 390(10110):2347\u20132359. https:\/\/doi.org\/10.1016\/S0140-6736(17)32400-5","journal-title":"Lancet"},{"issue":"1","key":"6833_CR352","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2337\/dc23-0636","volume":"47","author":"AA Sanusi","year":"2024","unstructured":"Sanusi AA, Xue Y, McIlwraith C et al (2024) Association of continuous glucose monitoring metrics with pregnancy outcomes in patients with preexisting diabetes. Diabetes Care 47(1):89\u201396. https:\/\/doi.org\/10.2337\/dc23-0636","journal-title":"Diabetes Care"},{"issue":"8","key":"6833_CR353","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2337\/dci19-0028","volume":"42","author":"T Battelino","year":"2019","unstructured":"Battelino T, Danne T, Bergenstal RM et al (2019) Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 42(8):1593\u20131603. https:\/\/doi.org\/10.2337\/dci19-0028","journal-title":"Diabetes Care"},{"issue":"1","key":"6833_CR354","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2337\/dc07-1066","volume":"31","author":"LR Nielsen","year":"2008","unstructured":"Nielsen LR, Pedersen-Bjergaard U, Thorsteinsson B, Johansen M, Damm P, Mathiesen ER (2008) Hypoglycemia in pregnant women with type 1 diabetes: predictors and role of metabolic control. Diabetes Care 31(1):9\u201314. https:\/\/doi.org\/10.2337\/dc07-1066","journal-title":"Diabetes Care"},{"issue":"1","key":"6833_CR355","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/AOG.0000000000000060","volume":"123","author":"BM Sibai","year":"2014","unstructured":"Sibai BM, Viteri OA (2014) Diabetic ketoacidosis in pregnancy. Obstet Gynecol 123(1):167\u2013178. https:\/\/doi.org\/10.1097\/AOG.0000000000000060","journal-title":"Obstet Gynecol"},{"issue":"7","key":"6833_CR356","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00592-024-02284-3","volume":"61","author":"T Teixeira","year":"2024","unstructured":"Teixeira T, Godoi A, Romeiro P et al (2024) Efficacy of automated insulin delivery in pregnant women with type 1 diabetes: a meta-analysis and trial sequential analysis of randomized controlled trials. Acta Diabetol 61(7):831\u2013840. https:\/\/doi.org\/10.1007\/s00592-024-02284-3","journal-title":"Acta Diabetol"},{"issue":"7","key":"6833_CR357","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1602494","volume":"375","author":"ZA Stewart","year":"2016","unstructured":"Stewart ZA, Wilinska ME, Hartnell S et al (2016) Closed-loop insulin delivery during pregnancy in women with type 1 diabetes. N Engl J Med 375(7):644\u2013654. https:\/\/doi.org\/10.1056\/NEJMoa1602494","journal-title":"N Engl J Med"},{"issue":"7","key":"6833_CR358","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.2337\/dc17-2534","volume":"41","author":"ZA Stewart","year":"2018","unstructured":"Stewart ZA, Wilinska ME, Hartnell S et al (2018) Day-and-night closed-loop insulin delivery in a broad population of pregnant women with type 1 diabetes: a randomized controlled crossover trial. Diabetes Care 41(7):1391\u20131399. https:\/\/doi.org\/10.2337\/dc17-2534","journal-title":"Diabetes Care"},{"issue":"17","key":"6833_CR359","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1056\/NEJMoa2303911","volume":"389","author":"TTM Lee","year":"2023","unstructured":"Lee TTM, Collett C, Bergford S et al (2023) Automated insulin delivery in women with pregnancy complicated by type 1 diabetes. N Engl J Med 389(17):1566\u20131578. https:\/\/doi.org\/10.1056\/NEJMoa2303911","journal-title":"N Engl J Med"},{"issue":"6","key":"6833_CR360","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S2213-8587(24)00089-5","volume":"12","author":"K Benhalima","year":"2024","unstructured":"Benhalima K, Beunen K, Van Wilder N et al (2024) Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial. Lancet Diabetes Endocrinol 12(6):390\u2013403. https:\/\/doi.org\/10.1016\/S2213-8587(24)00089-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"6833_CR361","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1089\/dia.2023.0323","volume":"25","author":"J Lawton","year":"2023","unstructured":"Lawton J, Kimbell B, Closs M et al (2023) Listening to women: experiences of using closed-loop in type 1 diabetes pregnancy. Diabetes Technol Ther 25(12):845\u2013855. https:\/\/doi.org\/10.1089\/dia.2023.0323","journal-title":"Diabetes Technol Ther"},{"key":"6833_CR362","doi-asserted-by":"publisher","unstructured":"Benhalima K, Polsky S (2025) Automated insulin delivery in pregnancies complicated by type 1 diabetes. J Diabetes Sci Technol 20(1):38\u201349. https:\/\/doi.org\/10.1177\/19322968251323614","DOI":"10.1177\/19322968251323614"},{"issue":"9","key":"6833_CR363","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1210\/clinem\/dgaf288","volume":"110","author":"JA Wyckoff","year":"2025","unstructured":"Wyckoff JA, Lapolla A, Asias-Dinh BD et al (2025) Preexisting diabetes and pregnancy: an Endocrine Society and European Society of Endocrinology joint clinical practice guideline. J Clin Endocrinol Metab 110(9):2405\u20132452. https:\/\/doi.org\/10.1210\/clinem\/dgaf288","journal-title":"J Clin Endocrinol Metab"},{"key":"6833_CR364","unstructured":"National Institute for Health and Care Excellence (2023) Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes [TA943]. Available from https:\/\/www.nice.org.uk\/guidance\/ta943. Accessed 2 June 2026"},{"key":"6833_CR365","unstructured":"NHS Digital (2026) National Pregnancy in Diabetes Audit - Hybrid closed loop 2025 (01 January 2025 to 31 December 2025). Available from https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/national-pregnancy-in-diabetes-audit\/2025#highlights. Accessed 14 July 2026"},{"issue":"7","key":"6833_CR366","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1055\/s-0036-1571323","volume":"33","author":"HA Roeder","year":"2016","unstructured":"Roeder HA, Moore TR, Ramos GA (2016) Changes in postpartum insulin requirements for patients with well-controlled type 1 diabetes. Am J Perinatol 33(7):683\u2013687. https:\/\/doi.org\/10.1055\/s-0036-1571323","journal-title":"Am J Perinatol"},{"issue":"6684","key":"6833_CR367","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1136\/bmj.298.6684.1357","volume":"298","author":"HA Davies","year":"1989","unstructured":"Davies HA, Clark JD, Dalton KJ, Edwards OM (1989) Insulin requirements of diabetic women who breast feed. BMJ 298(6684):1357\u20131358. https:\/\/doi.org\/10.1136\/bmj.298.6684.1357","journal-title":"BMJ"},{"issue":"8","key":"6833_CR368","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11892-024-01545-3","volume":"24","author":"MM Visser","year":"2024","unstructured":"Visser MM, Vangoitsenhoven R, Gillard P, Mathieu C (2024) Review article - diabetes technology in the hospital: an update. Curr Diab Rep 24(8):173\u2013182. https:\/\/doi.org\/10.1007\/s11892-024-01545-3","journal-title":"Curr Diab Rep"},{"issue":"10","key":"6833_CR369","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1007\/s00125-024-06206-4","volume":"67","author":"H Thabit","year":"2024","unstructured":"Thabit H, Schofield J (2024) Technology in the management of diabetes in hospitalised adults. Diabetologia 67(10):2114\u20132128. https:\/\/doi.org\/10.1007\/s00125-024-06206-4","journal-title":"Diabetologia"},{"issue":"5","key":"6833_CR370","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1177\/19322968221076562","volume":"17","author":"JJ Wright","year":"2023","unstructured":"Wright JJ, Williams AJ, Friedman SB et al (2023) Accuracy of continuous glucose monitors for inpatient diabetes management. J Diabetes Sci Technol 17(5):1252\u20131255. https:\/\/doi.org\/10.1177\/19322968221076562","journal-title":"J Diabetes Sci Technol"},{"issue":"7","key":"6833_CR371","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.2337\/dc20-2856","volume":"44","author":"GM Davis","year":"2021","unstructured":"Davis GM, Spanakis EK, Migdal AL et al (2021) Accuracy of dexcom G6 continuous glucose monitoring in non-critically ill hospitalized patients with diabetes. Diabetes Care 44(7):1641\u20131646. https:\/\/doi.org\/10.2337\/dc20-2856","journal-title":"Diabetes Care"},{"issue":"7","key":"6833_CR372","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.2337\/dc22-0073","volume":"45","author":"O Villard","year":"2022","unstructured":"Villard O, Breton MD, Rao S et al (2022) Accuracy of a factory-calibrated continuous glucose monitor in individuals with diabetes on hemodialysis. Diabetes Care 45(7):1666\u20131669. https:\/\/doi.org\/10.2337\/dc22-0073","journal-title":"Diabetes Care"},{"issue":"6","key":"6833_CR373","doi-asserted-by":"publisher","first-page":"956","DOI":"10.2337\/dc23-1663","volume":"47","author":"B Voglova Hagerf","year":"2024","unstructured":"Voglova Hagerf B, Protus M, Nemetova L et al (2024) Accuracy and feasibility of real-time continuous glucose monitoring in critically ill patients after abdominal surgery and solid organ transplantation. Diabetes Care 47(6):956\u2013963. https:\/\/doi.org\/10.2337\/dc23-1663","journal-title":"Diabetes Care"},{"key":"6833_CR374","doi-asserted-by":"publisher","first-page":"111986","DOI":"10.1016\/j.diabres.2024.111986","volume":"220","author":"G Cavalcante Lima Chagas","year":"2025","unstructured":"Cavalcante Lima Chagas G, Teixeira L, Clemente MRC et al (2025) Use of continuous glucose monitoring and point-of-care glucose testing in hospitalized patients with diabetes mellitus in non-intensive care unit settings: a systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 220:111986. https:\/\/doi.org\/10.1016\/j.diabres.2024.111986","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"6833_CR375","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1111\/dom.16297","volume":"27","author":"MT Olsen","year":"2025","unstructured":"Olsen MT, Jensen SH, Rasmussen LM et al (2025) Most hospitalised patients with type 2 diabetes benefit from continuous glucose monitoring compared to point-of-care glucose testing in a non-intensive care unit setting: a heterogeneity of treatment effect analysis. Diabetes Obes Metab 27(5):2857\u20132863. https:\/\/doi.org\/10.1111\/dom.16297","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"6833_CR376","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1007\/s00134-024-07663-6","volume":"50","author":"CG Nielsen","year":"2024","unstructured":"Nielsen CG, Grigonyte-Daraskeviciene M, Olsen MT et al (2024) Accuracy of continuous glucose monitoring systems in intensive care unit patients: a scoping review. Intensive Care Med 50(12):2005\u20132018. https:\/\/doi.org\/10.1007\/s00134-024-07663-6","journal-title":"Intensive Care Med"},{"issue":"10","key":"6833_CR377","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1089\/dia.2023.0304","volume":"25","author":"GM Davis","year":"2023","unstructured":"Davis GM, Hughes MS, Brown SA et al (2023) Automated insulin delivery with remote real-time continuous glucose monitoring for hospitalized patients with diabetes: a multicenter, single-arm, feasibility trial. Diabetes Technol Ther 25(10):677\u2013688. https:\/\/doi.org\/10.1089\/dia.2023.0304","journal-title":"Diabetes Technol Ther"},{"issue":"10","key":"6833_CR378","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.2337\/dc24-0626","volume":"47","author":"MY Lee","year":"2024","unstructured":"Lee MY, Seav SM, Ongwela L et al (2024) Empowering hospitalized patients with diabetes: implementation of a hospital-wide CGM policy with EHR-integrated validation for dosing insulin. Diabetes Care 47(10):1838\u20131845. https:\/\/doi.org\/10.2337\/dc24-0626","journal-title":"Diabetes Care"},{"issue":"6","key":"6833_CR379","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1177\/1932296820954163","volume":"14","author":"RJ Galindo","year":"2020","unstructured":"Galindo RJ, Umpierrez GE, Rushakoff RJ et al (2020) Continuous glucose monitors and automated insulin dosing systems in the hospital consensus guideline. J Diabetes Sci Technol 14(6):1035\u20131064. https:\/\/doi.org\/10.1177\/1932296820954163","journal-title":"J Diabetes Sci Technol"},{"issue":"1","key":"6833_CR380","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4158\/EP.15.1.24","volume":"15","author":"RM Bailon","year":"2009","unstructured":"Bailon RM, Partlow BJ, Miller-Cage V et al (2009) Continuous subcutaneous insulin infusion (insulin pump) therapy can be safely used in the hospital in select patients. Endocr Pract 15(1):24\u201329. https:\/\/doi.org\/10.4158\/EP.15.1.24","journal-title":"Endocr Pract"},{"issue":"6","key":"6833_CR381","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1177\/0145721705281563","volume":"31","author":"CB Cook","year":"2005","unstructured":"Cook CB, Boyle ME, Cisar NS et al (2005) Use of continuous subcutaneous insulin infusion (insulin pump) therapy in the hospital setting: proposed guidelines and outcome measures. Diabetes Educ 31(6):849\u2013857. https:\/\/doi.org\/10.1177\/0145721705281563","journal-title":"Diabetes Educ"},{"issue":"2","key":"6833_CR382","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.eprac.2020.09.012","volume":"27","author":"A Milluzzo","year":"2021","unstructured":"Milluzzo A, Falorni A, Brozzetti A et al (2021) Risk for coexistent autoimmune diseases in familial and sporadic type 1 diabetes is related to age at diabetes onset. Endocr Pract 27(2):110\u2013117. https:\/\/doi.org\/10.1016\/j.eprac.2020.09.012","journal-title":"Endocr Pract"}],"updated-by":[{"DOI":"10.1007\/s00125-026-06893-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000}}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06833-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-026-06833-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06833-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:42:11Z","timestamp":1790772131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-026-06833-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":382,"alternative-id":["6833"],"URL":"https:\/\/doi.org\/10.1007\/s00125-026-06833-z","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The units for C-peptide were corrected to pmol\/l (ng\/ml) in the caption of Fig. 1 and in the section on C-peptide measurement.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00125-026-06893-1","URL":"https:\/\/doi.org\/10.1007\/s00125-026-06893-1","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We acknowledge R. Bannuru, K. Balapattabi, N. El-Sayed, S. Challa SivaKanaka and R. Kalyani (ADA) and P. Niemann, M. Sch\u00f6nke, L. Rother, N Buckley-Muehge, M. Meireles and M. Osadolor (EASD), the Committee for Clinical Affairs and Board of the EASD and the Professional Practice Committee of the ADA for their coordination, guidance and support throughout the development process. We also acknowledge those who responded to the public consultation and thank the peer reviewers for their thoughtful input and valuable feedback, which helped strengthen the report. Finally, we acknowledge A. Jones (University of Exeter, Exeter, UK) for his invaluable and tireless help with Section\n                      \n                      , \u2018Diagnosis of type 1 diabetes\u2019. MSK and JP are editors of\n                      Diabetes Care\n                      but were not involved in any of the decisions regarding review of the manuscript or its acceptance.","order":1,"name":"Ethics","label":"Acknowledgements","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"No new data were created or analysed in this article. All data supporting the findings of this consensus report are available within the article and its electronic supplementary material, or from the references cited within the article.","order":2,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The report was jointly commissioned and funded by the ADA and EASD. The authors did not receive any payment for their involvement in the writing group.","order":3,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"RIGH has received honoraria for speaker engagements from Boehringer Ingelheim, Eli Lilly, Encore, Liberum, Novo Nordisk and ROVI Pharma and consultancy fees from Spotlight-AQ. JHD has served on an advisory board for Liom and was on a speaker\u2019s bureau for Novo Nordisk. He is a consultant for Gan & Lee. AH-F is\u00a0a member of the ADA Board of Directors, editor of ADCES in Practice and an auditor for the ADA\u2019s Education Recognition Program. She is a participant in a speaker\u2019s bureau for Abbott Diabetes Care and Xeris. She is also a member of Xeris\u2019s advisory board. IBH receives industry research funding from COUR Pharma and Tandem. He is a consultant for Roche and Abbott Diabetes Care. TK has served on advisory boards for Abbott, Ascensia, Bioton, Boehringer Ingelheim, Dexcom, Eli Lilly, Medtronic, Roche, Sanofi and Ypsomed. He has received research funding from Medtronic and is a participant in speakers\u2019 bureaus for Abbott, Ascensia, Bioton, Boehringer Ingelheim, Eli Lilly, Medtronic, Novo Nordisk, Roche, Sanofi and Servier. KN receives research funding from, is a member of the advisory board for and is a stockholder in Novo Nordisk. She is an advisory board member for Medtronic, Tandem, Convatec and Abbott Diabetes Care and receives research funding from Dexcom, Medtronic and Zealand Pharma. JP is a consultant to Sanofi, Novo Nordisk and Kriya therapeutics. ER serves on the advisory board for Abbott, Air Liquide SI, Dexcom, Insulet, Sanofi, Roche, Novo Nordisk and Eli Lilly and has received research support from Dexcom and Tandem. JSS is a member of the board of directors for Elvinix and SAB-BIO. He has been an advisor and consultant to 4Immune, AbbVie, Abvance, ActoBiotics, Adocia, AiTA, AstraZeneca, Avotres, Bayer, BiomeaFusion, COUR Pharmaceuticals, Dexcom, Eli Lilly, ICON, Immuthera, Inhale Biologics, Integrated Nanotherapeutics, i2o Inc, Kriya Therapeutics, Novo Nordisk, Oramed, Regor, Remedy Plan, Respond Health, Sanofi, Signos, Structure Therapeutics, Vertex, vTv and WiNK. He is a shareholder or option holder in 4Immune, Abvance, AiTA, Avotres, Dexcom, Elvinix, Oramed SAB-BIO, Signos, vTv and WiNK. FJS is a consultant for Abbott, Eli Lilly, Sanofi and Novo Nordisk and serves on the speakers\u2019 bureaus for Abbott, and Sanofi. He has received research funding from Sanofi and Novo Nordisk. RSW has received research funding from Eli Lilly, Tandem, Insulet, Diasome, DEKA Research and Development Corp\/Sequel Med Tech, MannKind and Amgen. ALP serves on the advisory board for Vertex Pharmaceuticals and Medscape. She has received research support from Abbott Diabetes Care, Insulet and Zucara. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.","order":4,"name":"Ethics","label":"Authors\u2019 relationships and activities","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"RIGH and ALP were co-chairs for the consensus statement writing group. AH-F, IBH, MSK, JP, JSS and RSW were the writing group members for the ADA. JHD, TK, BL, KN, ER and FJS were the writing group members for the EASD. All authors were responsible for drafting the article and revising it critically for important intellectual content. All authors approved the version to be published.","order":5,"name":"Ethics","label":"Contribution statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}